#### Anti-obesity interventions in Mexican Population

1 2	Looking for crumbs in the obesity forest: anti-obesity interventions in the Mexican population. History, and systematic review with Meta-Analysis
3	
4	Running title: Anti-obesity interventions in Mexican Population
5 6	Key words: Anti-obesity agents, abdominal obesity metabolic syndrome, systematic review, Meta- analysis, randomized clinical trials, type 2 diabetes (T2D).
7	The Síntevi Group
8	
9 10 11 12 13	Esperanza M. Garcia-Oropesa <sup>1</sup> <sup>†</sup> , Yoscelina E. Martinez-Lopez <sup>2</sup> <sup>†</sup> , Sonia María Ruiz-Cejudo <sup>3, 4</sup> , José Darío Martínez-Ezquerro <sup>3, 5</sup> , Alvaro Diaz-Badillo <sup>6,7</sup> , Carlos Ramirez-Pfeiffer <sup>7</sup> , Alejandra Bustamante-Fuentes <sup>8</sup> , Elena B. Lopez-Sosa <sup>9</sup> , Oscar O. Moctezuma-Chavez <sup>10</sup> , Edna J. Nava-Gonzalez <sup>11</sup> , Adriana L. Perales-Torres <sup>12</sup> , Lucia M. Perez-Navarro <sup>13</sup> , Marisol Rosas-Diaz <sup>1</sup> , Kathleen Carter <sup>14</sup> , Beatriz Tapia <sup>15</sup> , Juan C. Lopez-Alvarenga <sup>6,7*</sup>
14	
15 16	1 Laboratorio de Biología Molecular, Unidad Académica Multidisciplinaria Reynosa Aztlán (UAMRA), Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, Mexico.
17 18	2 Programa de Doctorado en Ciencias de la Salud. Universidad Nacional Autónoma de México (UNAM). Mexico City, Mexico.
19 20	3 Unidad de Investigación Epidemiológica y en Servicios de Salud, Área Envejecimiento (UIESSAE), Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS). Mexico City, Mexico.
21	4 Programa de Maestría y Doctorado en Música, Cognición Musical, UNAM, Mexico City, Mexico.
22 23	5 Centro de Ciencias de la Complejidad (C3), Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
24	6 Department of Human Genetics. University of Texas Rio Grande Valley. Edinburg, Texas.
25	7 Posgrado Universidad Mexico-Americana del Norte. Reynosa, Tamaulipas, Mexico.
26	8 Escuela de Medicina, Universidad Panamericana. Mexico City, Mexico.
27	9 Cirugía General. Hospital Español. Mexico City.
28	10 Asociación Odontológica Mexicana para la Enseñanza y la Investigación. Mexico City.

### Anti-obesity interventions in Mexican Population

- 11 Facultad de Salud Pública y Nutrición, Universidad Autónoma de Nuevo León, Monterrey, NuevoLeón, Mexico.
- 30 Leon, Mexico.
- 12 Laboratorio de Bromatología. Unidad Académica Multidisciplinaria Reynosa Aztlán (UAMRA),
   32 Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, Mexico.
- 33 13 Servicio de Nefrología, Dirección de Investigación, Hospital General de México Dr. Eduardo Liceaga,
   34 Mexico City.
- 14 Research and Education Library of the School of Medicine. Education & Academic Affairs. Universityof Texas Rio Grande Valley. Edinburg, Texas. United States of America.
- 37 15 Faculty Development, Associate Professor, Department of Pediatrics. University of Texas Rio Grande38 Valley. Harlingen. Texas.
- 39
- 40 <sup>†</sup> These authors have contributed equally to this work.
- 41 \*Correspondence:
- 42 Juan C. Lopez-Alvarenga
- 43 juan.lopezalvarenga@utrgv.edu
- 44
- 45
- 46 Tables in the manuscript: 5
- 47 Figures in the manuscript: 10
- 48 Supplemental tables: 2
- 49 Supplemental figures: 3
- 50

#### Anti-obesity interventions in Mexican Population

51

# 52 Abstract

53 Mexicans and Mexican Americans share culture, genetic background, and predisposition for chronic 54 complications associated with obesity and diabetes making imperative efficacious treatments and 55 prevention. Obesity has been treated for centuries focused-on weight loss while other treatments on 56 associated conditions like gout, diabetes (T2D), and hypertriglyceridemia. To date, there is no systematic 57 review that synthetize the origin of obesity clinics in Mexico and the efforts to investigate treatments for 58 obesity tested by randomized clinical trials (RCT).

- 59 We conducted systematic searches in Pubmed, Scopus, and Web of Science to retrieve anti-obesity RCT
- 60 through 2019 and without inferior temporal limit. The systematic review included RCT of anti-obesity
- 61 treatments in the Mexican adult population, including alternative medicine, pharmacological, nutritional,
- 62 behavioral, and surgical interventions reporting biometric outcomes such as BMI, weight, waist
- 63 circumference, triglycerides, glucose, among others. Studies with at least three months of treatment were
- 64 included in the meta-analysis.
- 65 We found 634 entries, after removal of duplicates and screening the studies based on eligibility criteria,
- we analyzed 43, and 2 multinational-collaborative studies. Most of the national studies have small sample
  sizes, and the studied strategies do not have replications in the population. The nutrition/behavioral
  interventions were difficult to blind, and most studies have medium to high risk of bias.
  Nutritional/behavioral interventions and medications showed effects on BMI, waist circumference, and
- 70 blood pressure. Simple measures like plain water instead of sweet beverages decrease triglycerides and
- 70 blood pressure. Simple measures like plain water instead of sweet beverages decrease digrycendes and 71 systolic blood pressure. Participants with obesity and hypertension can have benefic effects with
- antioxidants, and treatment with insulin increase weight in those with T2D.
- 73 The study of obesity in Mexico has been on-going for more than four decades, but the interest on RCT
- 74 just increased until this millennium, but with small sample sizes and lack of replication. The interventions
- affect different metabolic syndrome components, which should be analyzed in detail with the population
- 76 living on the U.S.-Mexico border; therefore, bi-national collaboration is desirable to disentangle the
- 77 cultural effects on this population's treatment response.

#### Anti-obesity interventions in Mexican Population

78

# 79 Introduction

Obesity phenotypes have been reproduced in arts and culture since the dawn of humanity. The Venus of 80 81 Willendorf, made 25 to 30,000 years BCE during the upper Paleolithic and currently exhibited in the 82 Natural History Museum in Vienna, is a figure depicting a woman with abdominal obesity symbolizing 83 femininity, beauty, and fertility. In Mexico the artistic expression in the well-preserved Bonampak, which 84 literally means painted wall, shows the Mayan ruling family of Bonampak, led by King Chaan Muwan 85 and his wife Lady Rabbit (1). The scenes painted between 790 and 792 AD show human figures with 86 signs of overweight or obesity. Other figurines from western Mexico show male abdominal distension, 87 some of them may represent fat, ascites, cancer, or other underlying conditions with controversial 88 significance (2).

89 For centuries, treatments for obesity have been described, mainly focused on weight loss and as a 90 treatment for other secondary conditions such as gout and diabetes. In Greek and Roman art, obesity 91 generated displeasure and sarcasm, being caricatured as an excess of alimentary and sexual stereotypes. 92 This deviation from the norm was unacceptable in ancient Greek art, and they called by the term 93 "Hippocratic Corpus" what we now call *morbid obesity*. The cause of obesity was considered the excess 94 of fluids circulating in the body, therefore, the treatment consisted of restricting the fluid balance through 95 diet, exercise, and medications. Since then, side effects of treatments have been described, like any 96 leanness of the body causes corrugation of the skin, or if a woman is pregnant there would be risk of 97 miscarriage.(3) The literature brought contrasting characters like Sancho Panza and Don Ouixote, or 98 Falstaff and Hamlet, stereotypes from Cervantes and Shakespeare, respectively. This jolly fat figure 99 remains in traditional celebrations like the image of Santa Claus contrasting with slim Scrooge (4).

100 In the eighteenth-century, the medical literature documented the association of obesity with fatigue, gout, 101 and breathing difficulties. Fat was considered reprehensible and medically undesirable. The progression 102 of nutrition as science with direct calorimetry measurement experiments from Atwater and Benedict (5) 103 between 1898 and 1900 analyzed the law of the conservation of energy applied to living organisms' 104 metabolism. They made a detailed description of demographic characteristics in men, diet, physical 105 activity recorded in their "Metabolism experiments". During the last century Vague (6) described the 106 well-known android and gynecoid morphologies. He measured the perimeter and thickness of adipose 107 tissue with calipers. Obesity has become a recognized clinical entity, subject of research and treatment 108 with medication and behavioral techniques.

- 109 In the United States, Mexican Americans are considered part of the Hispanic Americans or Latino group.
- 110 The U.S.-Mexico border represents this minority with active immigration, and a rapid increase in
- population. One of the Healthy People 2020 goals was to improve the health of all groups, requiring an
- understanding of the Hispanic culture, and health care needs for health promotion (7).
- 113
- 114

#### Anti-obesity interventions in Mexican Population

115 Obesity in Mexico, a story never told

The Obesity Clinic started in 1959 at the Instituto Nacional de Nutricion Salvador Zubiran, by Dr. Luis Domenge, Dr. Carmen Ramos and Dr. Jorge Gonzalez-Barranco. Obesity was considered as an aesthetic but also a medical problem. The so-called epidemiologic transition, from infectious to chronic degenerative diseases, moved slowly from the 70s and 80s. The evolution of treating obesity as a medical problem was promoted by Dr. Gonzalez-Barranco based on scientific research and clinical trials with medications in the 90s.

122 The first attempt to classify obesity was using the Metropolitan Life Insurance Company (MLIC) which 123 developed standard tables for "ideal" (MLIC 1942) and then "desirable" weight (MLIC 1959) based on 124 the observed association of body weight with mortality. These standard tables were the platform for 125 developing the current definition for underweight, normal, overweight, and obese individuals based on the 126 body mass index (BMI) cut-offs (8).

127 The use of BMI as a reliable measurement started with the NHANES from 1988 to 2016. These studies 128 demonstrated the age-adjusted prevalence of obesity in the United States increased progressively: from 129 22.9 to 39.6 percent. The main issue of concern in regard to BMI involves the growing obesity epidemic 130 and the increasing population with high BMI numbers (9).

131 Since 1993 a series of population surveys were conducted systematically in Mexico using the BMI. The 132 first National Survey on Chronic Diseases (ENEC from Spanish: Encuesta Nacional de Enfermedades 133 Crónicas) highlighted obesity as a national public health problem. The prevalence of obesity in Mexico 134 has increased substantially since the 1980s, and currently affects over 30% of the adult population (10). 135 The epidemiological transition from undernourishment and infectious diseases to emergent chronic 136 diseases were well documented in the ENEC. A sequel of undernourishment in presence of an obesogenic 137 environment is homeorrhexis as an adaptive response to undernourishment. Homeorrexis or homeorhesis 138 comes from the Greek homós, 'equal'; and rhéxis, 'violent rupture', and refers to regulatory mechanisms 139 that allow the body to change from one homeostatic, stable condition to another in a programmed fashion, 140 e.g. growth during childhood or the onset of lactation (11). A combination of genetic and socioeconomic 141 strata were conditions affecting stature. From North to South Mexico the ENEC data show a decrease in 142 stature by expenses of the lower body segment (Figure 1), the sitting height is almost similar across 143 regions. The stature can modify body composition despite BMI (12) and can be an indicator of 144 socioeconomic inequality (13).

The First Obesity meeting in Mexico with the NAASO and the Pan-American Endocrine Meetings were held in Cancun in 1997. These meetings were a landmark achievement for the study of obesity in Mexico with the first NOM (Mexican Official Norm) for obesity management, published in 1998 (14). Since this new millennium, there has been a spread of interest in obesity in other hospitals and Mexican states. Close collaboration with the Diabetes Division at the University of Texas San Antonio Health Science Center (UTSAHSC) and the South Texas Diabetes and Obesity Institute (STDOI) at the UTRGV has been done since then.

#### Anti-obesity interventions in Mexican Population

# 153 Importance of gathering scientific literature in Mexico

154 Mexican Americans are spread all over the United States, the National Health and Nutrition Examination

155 Surveys 1988-1994 showed children aged 4 to 17 years who born abroad had significantly lower

156 prevalence of overweight / obesity compared to Mexican American children born in the U.S. (PR = 0.77,

157 95% CI: 0.61, 0.96). In contrast, during 2005-2014, there was no evidence of a difference in overweight /

158 obesity at birth (PR = 0.95; 95% CI: 0.84, 1.07) and no differences with newer immigrants (<5 years

159 living in the U.S.) compared with those born in the U.S. (15).

160 Regarding the diet quality, Yoshida et al., (16) reported age differences in diet quality influenced by 161 acculturation (customary adoption of a new culture): older Mexican Americans had higher scores in 162 Healthy Eating Index (HEI) indicating a better diet quality. For vegetables, fruits, and proteins, middle-163 aged adults had higher scores compared to young adults. Concerning HEI components, a 1-unit increase 164 of acculturation was associated with 10% to 20% lower odds of attaining better scores for vegetables, 165 fruits, doiny, and ampty colorizes in almost all ages

165 fruits, dairy, sodium, and empty calories in almost all ages.

166

# 167 Medication research and current anti-obesity guidelines

Some pharmacokinetics determinants of many drugs depend on the body size; for instance, obesity
modifies the volume of distribution, and drug clearance, probably due to increased activity of cytochrome
P450 2E1 and possible modifications on tubular reabsorption (17).

171 However, not only biology can explain the variability on losing weight, other factors are associated with 172 the feasibility of following medical recommendations affected by cultural environment. The importance 173 of lifestyle was defined in early times of weight loss intervention but was debated by the use of 174 medication.

Numerous international published guidelines for anti-obesity treatment consider the local disparities and cultural differences of each geographic region. The management of obesity relies on diverse medical specialists, health professionals and government decisions. Primary prevention of obesity is fundamental and requires policies for favoring spaces for physical activity and a healthy environment. Harmonization on treatment cannot be global but can help to tailor weight loss treatments, and metabolic improvement for prevention of complications.

181 Since 2000 guidelines from the former North American Association for Study of Obesity (nowadays The 182 Obesity Society -TOS) and the NIH Working Group were mainly based on dietary therapy, physical 183 activity, and behavior therapy, and guided on the appropriate use of pharmacological and surgical 184 interventions. The weight loss recommendation was for patients with BMI >30 and those with BMI 185 between 25 and less than 30 with two or more complications. They suggested that pharmacotherapy 186 should be used only in the context of a treatment program with diet, physical activity, and behavior 187 therapy. Once the guide was published, only two drugs were approved for weight loss, sibutramine and 188 orlistat (18).

### Anti-obesity interventions in Mexican Population

189 The European guidelines also made emphasis on lifestyle modifications including nutrition and physical 190 activity. The goals are risk reduction (even with modest weight loss i.e. 5-10% of initial body weight), 191 attention on waist circumference and management of complications. They increase the number of drug 192 treatments for obesity approved by FDA (Food and Drug Administration) and EMA (European Medicines 193 orlistat, lorcaserin (only for FDA), phentermine/topiramate (only for FDA), Agency): 194 bupropion/naltrexone and liraglutide. They recommend drug discontinuation if the patient does not reach 195 5% loss of initial weight after 12 weeks of treatment. This guide discusses metabolic surgery focusing on 196 metabolic effects as primary outcomes instead being limited to weight loss (19).

197 The Endocrine Society in 2015 published the guideline for pharmacological management of obesity (20)
198 implementing diet, exercise, and behavioral modification and suggesting drugs may amplify adherence to
199 behavior change, especially for patients with a clinical history of failure in non-medication treatments.

200 The nutritional health status in Mexico was affected by government policies, the first supermarket chains 201 selling American processed food in Mexico started in the 1940s. The government eliminated the subsidy 202 of corn tortillas in 1999 with the objective to improve competitiveness in the global economy. This action 203 loaded in closedown local tortilla factories not able to compete. The transition epidemiology from 204 infectious to chronic diseases was rampant in this period. In 2008 the import tariffs on maize, bean, sugar, 205 and mill were eliminated. In response to the nutritional problems and increase in obesity, in 2010 the 206 Ministries of Public Education and of Health published the General Guidelines for Dispensing or 207 Distribution of Foods and Beverages at School Food Establishments (SFEs). After a mass media 208 campaign to reduce consumption of high caloric food, the Mexican congress, in 2014, excised a tax on 209 high energy dense food (21).

This study aims to perform a systematic review with meta-analysis to synthesize and evaluate the evidence of anti-obesity treatments performed in Mexican adults with overweight and obesity. These treatments can include pharmaceutical, behavioral, surgical, nutritional, and alternative interventions designed as controlled clinical trials, to compare results within and between interventions, and finally, to discuss these findings with Mexican American studies.

Anti-obesity interventions in Mexican Population

216

# 217 Methods

## 218 Protocol registration and search strategy

219 The protocol was registered in PROSPERO on 11/17/2020 and assigned the registry number 220 CRD42020221436. The search strategies included Pubmed, Scopus, and Web of Science databases to 221 obtain published literature up to 2019 to include randomized controlled clinical trials for obesity 222 conducted in Mexico. To identify additional studies and gray literature, we contacted Medical Societies 223 such as the Endocrinology Society from Mexico and researchers from academic institutions such as 224 UNAM. For inclusion in the meta-analysis, all interventions had to be conducted for at least three months 225 and report both baseline and final BMI. The query was focused on all interventions with overweight or 226 obese participants who underwent weight loss treatment. We included nutritional/behavioral treatments, 227 with knowledge that many of these interventions cannot be blinded, therefore we assessed the possibility 228 of bias using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 229 approach (22). Medications, alternative medicine and surgical interventions were included in the review 230 finished in December 2020.

231 An example of a search strategy performed in Pubmed without time period limits:

(("obesity"[MeSH Terms] OR "obesity"[All Fields]) AND ("therapy"[Subheading] OR "therapy"[All
Fields] OR "treatment"[All Fields] OR "therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]))
AND ("mexico"[MeSH Terms] OR "mexico"[All Fields]) AND Clinical Trial[ptyp]

235

# 236 Eligibility criteria

237

238 The systematic review included Mexican adult overweight or obese participants in controlled clinical 239 trials subjected to pharmaceutical, behavioral, surgical, nutritional, or alternative interventions. Weight 240 loss was the primary or secondary outcomes. We included studies published in English or Spanish at any 241 time, conducted in Mexican centers and multicentric international studies with Mexican participants. For 242 inclusion in the meta-analysis, treatments had to be conducted for at least three months and indicate 243 baseline and final BMI. When available, we analyzed metabolic syndrome components (i.e., serum 244 concentration of glucose, HDL-C, triglycerides, systolic and diastolic blood pressure, and waist 245 circumference). We followed these criteria for the articles' peer-screening and conducted a third final group review to resolve disagreements. We contacted the corresponding authors to clarify doubts and 246 247 obtain additional information when necessary.

248

## 249 Studies selection

250 We recovered 634 studies from three databases: Pubmed (n=180), Scopus (n=238), and Web of Science 251 (n=216). After eliminating duplicate studies and applying the eligibility criteria, 589 studies were

eliminated. The flux of the analyzed studies is described in Figure 2. Of the 45 included studies data were

#### Anti-obesity interventions in Mexican Population

extracted using the Cochrane tool and quality assessed with the Jadad scale. There were 45 studies included in the qualitative synthesis and 25 in the meta-analysis. Of the studies included in the qualitative synthesis, 55 interventions were described: 25 with medications, 27 with nutrition and exercise, and 3 with surgical treatment (Table 1).

257

258 Data extraction process

259

260 The data extraction from the studies was done, by a team of 13 researchers, with a modified Cochrane 261 tool for data collection form to obtain detailed information: type of intervention (drug, nutritional 262 programs, behavioral treatments, use of drugs, surgical interventions or alternative medicine), age of 263 intervention (childhood, adult), duration of treatments, year of the study development, sample size, groups 264 of intervention, blindness of the treatment and the size of effects obtained in each study (Cohen's d). 265 Data extraction was performed in duplicate, and cases of discrepancy were re-analyzed in groups of 4 266 investigators. When it was necessary, authors were contacted to collect additional information. The main 267 outcome was related with the reduction of BMI, waist circumference or percentage of body fat and 268 biochemical parameters such as glucose, total cholesterol, triglycerides, HDL-c, blood pressure, HOMA-269 IR and Matsuda. WE used meta-regression to analyze the source of heterogeneity with mean age, mean 270 BMI, location of the study (represented as latitude of the city of recruitment), sex distribution, and 271 duration of the study. Adverse effects were also analyzed.

272

The quality assessment of the studies was done using the Jadad scale (23) and the risk of bias wasassessed with GRADE checklist (22) with the following assessment guidelines:

275 Low risk studies were treatment with unpredictable allocation: A central office for allocation by phone, 276 web, and pharmacy. Use of sequentially numbered, sealed, opaque envelopes. The drug containers are 277 sequentially numbered and identical. Meanwhile high risk is predictable allocation, like staff know the 278 random sequence in advance. Another high risk of bias was the use of envelopes or packaging without 279 safeguards or non-random, predictable sequence. The attrition bias can be considered if there was a poor 280 description on how much data was missing from each group, or the lack of reasons for missing data and 281 how they were considered in the analysis. We were also interested in whether researchers used intention 282 to treat analysis, imputation of missing values, or just per protocol analysis.

283

## 284 Statistical analysis

285

The obtaining of sample size, means, and standard deviation was done with the data from the included studies. The summary of contrast was computed with Cohen's-d differences. All models were analyzed with Restricted maximum likelihood (REML) random effects models, and the pooled effects were described with 95% confidence intervals. Heterogeneity was assessed with I^2 statistics, and we use meta-regression to analyze the heterogeneity. These statistical analyses were conducted with Stata 16.0 (StataCorp, College Station TX).

The network meta-analysis was computed for studies with medication only, because the designs of nutrition/behavior studies did not allow us to build nets. The analysis was performed with Stata 16.0 and

#### Anti-obesity interventions in Mexican Population

- 294 CINeMA to define the network geometry, and effects comparisons. We did not have enough samples of
- studies to perform a rankogram.

Anti-obesity interventions in Mexican Population

# 297 Results

We collected 634 studies from databases and after duplicate removal identified 64 controlled clinical
 trials from PubMed, 27 from Scopus and 15 from Web of Science conducted in Mexico.

# 300 Studies characteristics

We included 45 anti-obesity national and multinational collaborative controlled clinical trials involving
overweight and obese Mexican adults (>18 yr) subjected to distinct weight-loss interventions:
pharmaceutical (25 studies), nutrition and behavioral (15 studies), surgical (2 studies), and alternative (3
studies) interventions (Table 1). Overall interventions included exclusively women were 15, men 5, and
both sexes 35.

## 306 Participant cities

307 Considering 45 interventions from 25 studies used in the quantitative analysis, Mexico City had the

highest frequency of studies 38% (n=17), followed by Guadalajara 29% (n=13). The states close to the
 U.S. border were three (Nuevo Leon, Tamaulipas and Baja California). The details are described in Table

**310** 1.

# 311 Risk of bias and quality

We performed a quality assessment at the intervention level. The Jadad mean value for nutritional/behaviour interventions was 3.6 (min 3, max 5), and for drug treatments was 3.7 (min 2, max 5). The nutrition/behaviour interventions had medium risk of bias (by GRADE) in 95% (n=18/19) and high risk of bias in 5% (n= 1/19). Physical activity was difficult to blind. The use of medication as intervention had very low risk of bias in 32% (n=7/22), medium 55% (n=12/22) and high risk in 14% (n=3/22). No differences in bias were found for intervention including T2D participants (Fisher's exact test= 0.286).

# 319 Synthesis of results

This meta-analysis included data from 2074 participants in nutrition/behaviour interventions and 5086 participants with medication, if we exclude multicentric international studies there were 1525 participants from studies exclusively made in Mexico. The main outcomes from individual studies are described in Tables 2 to 4. The forest plots with the pooled analysis are in Figures 3 to 10.

# 324 Nutritional/Behaviour interventions

The comparisons between active nutrition/behavior interventions with placebo showed improvement for BMI [Cohen-d, 95% CI, Figure 3] 0.2 (0.01, 0.38), waist circumference 0.27 (0.01, 0.53, Figure 4), triglycerides 0.34 (-0.02, 0.71; Figure 5), and systolic blood pressure 0.21 (-0.07, 0.49, Figure 6). The

#### Anti-obesity interventions in Mexican Population

- 328 lowest heterogeneity was for BMI ( $I^2 = 41\%$ ) and the highest for triglycerides ( $I^2 = 88\%$ ). Only one
- 329 intervention with physical activity showed an effect on BMI (Cohen-d of 0.3), increase on HDL-c
- 330 (Cohen-d 0.16), but with wide confidence intervals. Most of these studies excluded T2D individuals,
- therefore the glucose levels did not show difference between compared groups.

The addition of adding CBT (goal setting, problem-solving, and stimulus control) to either a low-fat diet (21% fat, less than 10% saturated fat, 25% protein, 54% carbohydrates), or a low-carbohydrate diet (27% protein, 28% fat, 45% carbohydrate) produced significantly greater short-term weight loss compared with diet alone. The use of antioxidants with flavonoids contained in dark chocolate showed favorable changes in biochemical parameters (total cholesterol, triglycerides, and LDL-cholesterol level in blood) and anthropometrical parameters (waist circumference) the pooled analysis with Cohen-d supported additionally loss of BMI and decrease in systolic blood pressure (Figure 6).

Finally, the avoid of sugar-sweetened beverages (SSB) by water substitution showed positive effect onplasma triglycerides, and systolic blood pressure.

# 341 Drug treatments and T2D status

Drug treatment analyzed studies which involved participants with T2D. The size of effect showed
improvement on BMI (Figure 7), waist circumference (Figure 8) and glucose (Figure 9) for non-T2D
individuals compared with patients with T2D. The BMI loss in T2D group had a Cohen-d of 0.24 (0.13,
0.66) compared with non-T2D loss of 0.53 (0.27, 0.80); the waist circumference was Cohen-d 0.22 (0.72,
1.16) compared with non-T2D 0.55 (0.03, 1.07); diastolic blood pressure 0.18 (0.3, 1.42) vs 0.87 (0.33,
2.06), respectively. As expected, the treatment had large effect on glucose lowering for treated T2D
individuals compared with non-T2D (Cohen-d 0.7 compared with 0.26, respectively).

349 Some medications used in Mexico had a large effect on weight reduction (Figures 7 and 8) in participants 350 without T2D (Cohen-d about 0.9). For instance, the use of DHA (docosahexanoic acid) 470 or 940 mg 351 combined with EPA (eicosapentanoic acid) 580 or 1160 mg, compared with placebo, and the use of two 352 different formulations (Formula 1: d-norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg, 353 atropine 0.36 mg, aloin 16.2 mg; and formula 2: d-norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 354 16.2 mg.) for 6 months compared with placebo. These medications are not approved for treatment of 355 obesity by FDA, and the formulations are not legally available for purchase in the US, however, reports in 356 US found thyroid intoxication (70). The effect of liraglutide was between 0.3 to 0.6 including participants 357 from international samples. Participants with T2D showed the use of phentermine 15 mg and topiramate 358 100 mg had higher effect compared with phentermine 7.5 mg and placebo. There was no replication for 359 any of these studies, the Egger test on a random model showed no small study effects on BMI for 18 360 intervention on nutrition/behavior (p=0.43), nor for 19 intervention on medication (p=0.22).

361 It is interesting that systolic blood pressure was modified by non-pharmacological treatments, meanwhile, 362 diastolic blood pressure was modified in non-T2D participants treated with medications (Figure 10). 363 From the five analyzed studies with medications, three of them included patients with hypertension. The 364 prevalence of hypertension was between 24 to 42%. The blood pressure decreases with weight loss, the 365 Trial of Hypertension Prevention had a weight loss intervention arm, resulting in reduction of both, 366 systolic and diastolic, measurements (71).

#### Anti-obesity interventions in Mexican Population

### 367 Study heterogeneity sources

368 The meta regression analyzed the mean age, BMI, months of treatment, comparison with placebo and 369 geographical location measured by latitude. Those confounders that reached statistical significance for 370 HDL-c serum levels were the duration of the intervention [b=1.07 (se 0.49) p=0.03] and the comparison 371 vs placebo [b=4.4 (se 2.1) p=0.04]. The triglyceride serum levels showed effects from the mean age of the 372 study [b=1.3 (se 0.59) p=0.03] and the geographic location [b= -2.7 (se 1.3) p=0.04]. However, the 373 geographic location was close related with the type of intervention, for example, studies located close to 374 the U.S.-Mexico border used physical activity interventions; meanwhile the South regions used 375 nutritional supplements. The diastolic blood pressure was modified by the BMI [b=-0.49 (se 0.27) 376 p=0.067] and geographical location [b= - 0.9 (se 0.44) p=0.04], however these variables were influenced 377 by the treatment with liraglutide. [Supplemental Figures 1 and 2]

#### 378 Network meta-analysis

379 A network meta-analysis of drug treatments and T2D status was performed for BMI, diastolic blood 380 pressure (DBP), and glucose. The network meta-analysis included direct comparisons constructed with 381 connections between treatments, and indirect comparisons using all possible connections between 382 treatments. All networks had the principles of coherence, transitivity, and consistency. This analysis was 383 not feasible for nutritional/behavior interventions due to the design and the small number of studies. 384 Figure 11 illustrates two networks for studies with T2D patients, examining the efficacy of 385 pharmacological interventions on the studied variables, one network for each comparison between 386 treatments and placebo (Supplemental figure 3 panel A) and with metformin (Supplemental figure 3 panel 387 B). These network diagrams provide a graphical representation of how each intervention connects to any 388 other direct comparisons. Tables 5 (matrix A and B) and Supplemental Tables 1 and 2 detail the complete 389 matrix of results, in which the comparative effects between drugs are shown in terms of differences in 390 means standardized.

391 The contrast matrix between pharmacological treatments with placebo showed a decrease on BMI by any 392 pharmacological intervention, for instance, DHA 470 mg + EPA 580 mg was 0.816 (CI: 0.049, 1.582); 393 DHA 940 mg + EPA 1160 mg: 0.888 (CI: 0.117, 1.658); Formulation 1: 0.959 (CI: 0.324, 1.593); 394 Formulation 2: 0.944 (CI: 0.301, 1.588); Liraglutide: 0.451 (CI: 0.141, 0.761). On the other hand, the 395 status of T2D consistently supported metformin alone and in combinations were the most effective 396 intervention for reducing BMI compared to insulin: -0.898 (CI: -1.431, -0.366). Regarding glucose, the 397 intervention with insulin was more effective in reducing serum glucose levels compared to metformin: -398 1.506 (CI: -2.084, -0.928); Glimepiride + metformin: -1.332 (CI: -2.083, -0.581) and Glimepiride: -1.332 399 (CI: -2.077, -0.587). In summary, the interventions with the greatest contribution to the reduction of DBP 400 were metformin: -0.507 (CI: -0.994, -0.020) compared to Glimepiride + metformin, and Glimepiride: -401 0.507 (-0.980, -0.033) compared to Glimepiride + metformin. The monotherapy interventions have better 402 effectiveness in DBP compared to double therapies.

#### Anti-obesity interventions in Mexican Population

403

# 404 Discussion

405 This systematic review and meta-analysis summarize the existing evidence of weight loss as primary or 406 secondary aims in adult population. Our analysis was limited to randomized clinical studies conducted in 407 Mexico or from international multicentric studies with Mexican participants involving nutrition, behavior, 408 medication, or alternative medicine interventions. Some interventions of interest were compared with 409 another active strategy (medication, behavior, physical activity or any different than placebo), this 410 strategy can blunt the size of effect of the intervention, because the effect of active comparators in 411 metabolic and anthropometric variables. We found that all studied interventions were better than placebo, 412 or better than the selected comparator, and many of the published papers made individual paired contrasts 413 between final and basal values. However, we decided to contrast treatments and reported the size of 414 effects by metabolic syndrome component. With this strategy we had the advantage of computing the 415 effect size over a maneuver the researchers considered the best comparator. The results should be 416 interpreted considering these control groups defined by the researchers.

### 417 Interventions

The 55 analyzed interventions (from 45 studies) were categorized in nutritional/behavior with a total sample of 1,407 participants; drug interventions in Mexico included 1,134; and multinational interventions were additional 1,307 participants (Hispanics); surgical procedures were 72 and alternative treatments 235 individuals. We obtained a total of 4,155 participants from these trials.

422 The nutritional/behavior strategies included supplemental, flavonoids, manipulation of macronutrient 423 content diets (low fat, low carb, high protein) with caloric restriction, water consumption and physical 424 activities. Cognitive behavioral therapy (CBT) combined with low calorie diet showed beneficial effects 425 on BMI and waist circumference; and combined with low fat diet deceased glucose, triglycerides. A 426 cardioprotective structured hypocaloric diet is more effective than the CBT approach in reducing 427 metabolic syndrome (59). Daily flavonoid-rich chocolate (70% cocoa) intake improves fasting plasma 428 glucose levels and insulin resistance parameter (HOMA-IR) and the lipid and glucose metabolism (46). 429 The physical activity showed benefic but small and non-significant effects for the analyzed variables, due 430 to the lack of enough sample size. Other systematic reviews focused on physical activity showed 431 Hispanics had less leisure-time compared with other groups in the U.S., the most common activity was 432 walking, but the most significant results were those with moderate to vigorous physical activity (72). It 433 will be crucial to increase legislative policies to build environments that increase available opportunities 434 for physical activities, particularly for this fast-growing population group.

Adherence to diet and exercise programs (45 min-60 min/d, 5 days per week) are part of the nutritional/behavioral interventions. Other studies reporting that water consumption habit (2–3 L/day) and partially decreasing sugar-sweetened beverage (SSB) intake of at least 250 kcal/d, with nutritional counseling was effective in increasing water intake (69), and additionally reduces cardiometabolic risks of drinking or eating less sugar in the diet promoting health benefits, although we found positive effect on

#### Anti-obesity interventions in Mexican Population

plasma triglycerides and systolic blood pressure in our analysis, perhaps a consequence of the reductionof the SSB consumption.

The drug treatment with groups of participants with T2D, showed small effect size on improvement on BMI, waist circumference and triglycerides compared with larger effects for non-T2D. The orlistat group in T2D showed weight loss (BMI and waist circumference) lower level of glucose, triglycerides, and systolic blood pressure. Comparing these findings with other studies made in Mexican Americans living in the border shows the difficulty of losing weight with programs on self-management education, but the HbA1c improved (73). No medication will overcome unhealthy lifestyles.

448 Medication showed a larger size of effects on BMI for combined formulations like orlistat, phentermine 449 with topiramate, both approved by regulatory agencies. Other formulations like the combination of 450 triiodothyronine with phentermine (non-approved by FDA but approved by COFEPRIS - Federal 451 Committee for Protection from Sanitary Risks), and combination of DHA and EPA showed effect on 452 BMI. The authors of the formulations did not show the result on serum glucose neither reported any 453 adverse effect. There was no replication for any of these treatments. We found a couple of sibutramine 454 trials. This is a retired medication because the cardiovascular risk was greater than the benefits (74), 455 specially for the difficulty to identify patients with silent cardiovascular disease (75).

456 Surgical intervention is the most effective treatment for patients with morbid obesity.(76) The percentage 457 of body weight loss with this intervention ranges between 33 and 77% in a period of 24 months, thus 458 demonstrating its effectiveness (77, 78). However, in our surgical papers, no significant differences were 459 found in the percentage of weight loss, this due to the fact that both the intervention group and the control 460 group had equivalent surgeries (79). One of the studies compared banded versus unbanded laparoscopic 461 roux-en-Y gastric bypass and follow up weight changes for 24 months,(67) in a second analysis no 462 differences were found between these procedures after five years of follow up (66).

463

### 464 Risk of bias

465 In general, many of the studied interventions are challenging to blind for obvious reasons. For example, a 466 comparison of nutritional interventions vs. exercise or CBT cannot be blind. However, there is a 467 possibility to blind the evaluators, but no studies explicitly describe this strategy. We found that 468 heterogeneity of the results were partially attributable to basal differences between contrasting groups, for 469 example in the study of Rosado et al., (51) the diastolic and systolic blood pressure were significantly 470 different between the studied low fat milk groups compared with controls. Some surgical studies for 471 weight loss made in the Instituto de Nutricion Salvador Zubiran in Mexico City blinded the abdominal 472 wall for patients and evaluators when they compared the open abdominal approach versus the 473 laparoscopic method. The risk of bias can be lessened but still can compromise the results of the studies. 474 The difficulty in addressing nutritional or behavioral interventions is manifest in studies analyzing 475 racial/ethnic disparities. Multilevel church-based interventions considering socio-ecological influence 476 showed a greater impact if they consider program interventions tailored to specific communities.

477 Limitations

#### Anti-obesity interventions in Mexican Population

478 The most important limitations are the lack of replication studies with the same medications, and the 479 small sample size for most of the studies. There was wide variety in the criteria for selection of the 480 participants (i.e.: some studies had too specific eligibility criteria for sex, age and BMI compared with 481 other studies with wide range of options), and, despite similar genetic background, the participants live in 482 sites embedded in cultural diversity (i.e.: Mexico City's environment problems differ from those in States 483 close to the U.S.-Mexico border). We address a broad question regarding the metabolic syndrome 484 components with important heterogeneity of the studies. We addressed this problem using meta-485 regression to statistically weight the main confounders across studies and the use of a network meta-486 analysis to compute the magnitude of contrasts between treatment effects. Due to these limitations the 487 obtention of unstable coefficients is possible, therefore, the analysis should be repeated in the future with 488 a greater number of studies.

The small sample sizes from many of the included studies resulted in low statistical power for contrasting between treatment, and the lack of replication studies increased the standard error for the analysis. The new medications approved by FDA have been tested scarcely in Mexican population. About 44% of the studies were performed in the limit time of placebo effects (about 12 weeks), but those with more time showed effects on the HDL cholesterol levels.

Future new and replication studies should consider larger periods for treatments to reduce placebo effects.
Future reviews and meta-analysis should analyze anti-obesity interventions in children and adolescents as
well old age populations. These suggestions agree with the Healthy People 2030 recommendation on
study effective strategies to diminish obesity in children and adolescents (80).

498 The Mexican states conducted research in anti-obesity interventions were ten from 32 states. The U.S.-499 Mexico border has sister states: California-Baja California, Arizona-Sonora, New Mexico-Chihuahua, 500 Texas with Chihuahua, Coahuila, Nuevo Leon and Tamaulipas. The Binational initiative should improve 501 the collaborative studies in the U.S.-Mexico border to address interventions in this population. The 502 programs from this initiative addresses environmental protection, communication committees in 503 particular communities (81). The U.S.-Mexico Border Health Commission has agreements with the 504 Secretary of Health from both countries, and this agency supports initiatives in health security (82). The 505 programs include prevention and wellness using guidelines for eating healthy, physical activity, and of 506 drug misuse and abuse prevention.

507

## 508 Conclusions

509 Since 1996, anti-obesity interventions have been conducted in Mexico in randomized controlled clinical 510 studies, mainly focused on pharmaceutical, nutritional, or physical activity interventions. Adult 511 participants included in these studies were predominantly from the central and northern Mexican states, 512 with a clear absence from the costal and southern states. Anti-obesity studies in the Mexican population 513 include small samples and reduced time for interventions. A strategy to improve the statistical power for 514 the studies is to conduct multicentric studies, and a compromise for the State or private industries to

515 provide sufficient finantial resources.

### Anti-obesity interventions in Mexican Population

516 A national web of research is feasible for answering relevant questions regarding anti-obesity 517 interventions and its metabolic consequences. It is clear that not all metabolic syndrome components have 518 the same response to the intervention. The inclusion of Mexican Americans and Mexican immigrants 519 living in the U.S. would be desirable to clarify the importance of different techniques to tackle this 520 problem.

#### 521 Acknowledgement

We thanks Dr.Victoria Valles from the National Institute of Medical Sciences and Nutrition Dr. Salvador
Zubiran (INCMNSZ) for the share of invaluable experience about the ENEC-93. Last, we would like to
pay our gratitude and our respects to Dr. Gonzalez-Barranco. He was a pioneer in obesity research since
1970s, Dr. Gonzalez-Barranco passed away in December of 2020.

526

527	Funding
528	
529	

#### Anti-obesity interventions in Mexican Population

531

# 532 References

- 535 Finegold A. Dramatic Renditions: Battle Murals and the Struggle for Elite Legitimacy in 1. 536 Epiclassic Mesoamerica: Columbia University; 2012. 537 DeSmet P. Figurines with distended abdomen from ancient Western Mexico2020 January 5th, 2. 538 2021]. Available from: https://www.academia.edu/Documents/in/Pre-Columbian Art 539 3. Christopoulou-Aletra H, Papavramidou N. Methods used by the hippocratic physicians for weight 540 reduction. World J Surg. 2004;28(5):513-7. 541 Eknoyan G. A history of obesity, or how what was good became ugly and then bad. Adv Chronic 4. 542 Kidney Dis. 2006;13(4):421-7. 543 5. Atwater WOB, F. G. . Experiments on the metabolism of matter and energy in the human body. 544 In: USDA Office of Experiment Stations B, editor. Washington DC: Government Printing Office; 1902. 545 p. 150. 546 Vague J. Sexual differentiation. A determinant factor of the forms of obesity. 1947. Obes Res. 6. 547 1996;4(2):201-3. 548 Services USDoHaH. Healthy People 2020: United States Department of Health and Human 7. 549 Services, Washington, DC; 2010 [Available from: https://www.healthypeople.gov/2020/About-Healthy-550 People. 551 Komaroff M. For Researchers on Obesity: Historical Review of Extra Body Weight Definitions. J 8. 552 Obes. 2016;2016:2460285. 553 9. Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. StatPearls. Treasure Island 554 (FL)2020. 555 10. Rtveladze K, Marsh T, Barquera S, Sanchez Romero LM, Levy D, Melendez G, et al. Obesity 556 prevalence in Mexico: impact on health and economic burden. Public Health Nutr. 2014;17(1):233-9. 557 Kondrup J. Basic concepts in nutrition: Energy and protein balance. e-SPEN, the European e-11. 558 Journal of Clinical Nutrition and Metabolism [Internet]. 2008; 3:[e117-e20 pp.]. 559 Lopez-Alvarenga JC, Montesinos-Cabrera RA, Velazquez-Alva C, Gonzalez-Barranco J. Short 12. 560 stature is related to high body fat composition despite body mass index in a Mexican population. Arch 561 Med Res. 2003;34(2):137-40. 562 Castro-Porras LV, Rojas-Russell ME, Aedo-Santos A, Wynne-Bannister EG, Lopez-Cervantes 13. 563 M. Stature in adults as an indicator of socioeconomic inequalities in Mexico. Rev Panam Salud Publica. 564 2018;42:e29. 565 Salud Sd. NORMA OFICIAL MEXICANA NOM-174-SSA1-1998, PARA EL MANEJO 14. 566 INTEGRAL DE LA OBESIDAD. 1998. 567 15. Maldonado LE, Albrecht SS. Does the Immigrant Advantage in Overweight/Obesity Persist over 568 Time in Mexican American Youth? NHANES 1988-1994 to 2005-2014. Obesity (Silver Spring). 569 2018;26(6):1057-62. 570 16. Yoshida Y, Scribner R, Chen L, Broyles S, Phillippi S, Tseng TS. Role of Age and Acculturation 571 in Diet Quality Among Mexican Americans - Findings From the National Health and Nutrition 572 Examination Survey, 1999-2012. Prev Chronic Dis. 2017;14:E59.
- 573 17. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in
  574 humans. Clin Pharmacokinet. 2010;49(2):71-87.
- 575 18. Initiative NOE. The practical guide. Identification, evaluation, and treatment of overweight and576 obesity in adults. NIH publication Number 00-4084. 2000.
- 577 19. Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European Guidelines for
  578 Obesity Management in Adults. Obes Facts. 2015;8(6):402-24.

### Anti-obesity interventions in Mexican Population

- 579 20. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al.
- 580 Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin
  581 Endocrinol Metab. 2015;100(2):342-62.
- 582 21. Ehara T. Mexico and its obesity epidemic. Global Food Cultures [Internet]. 2018. Available from:
   583 https://wp.nyu.edu/steinhardt-gfcmexico2018/2018/04/11/mexico-and-its-obesity-epidemic/.
- 584 22. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to
  585 aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev.
  586 2014;3:82.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the
  quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-
- 589 Î2.
- 590 24. Gonzalez-Heredia T, Hernandez-Corona DM, Gonzalez-Ortiz M, Martinez-Abundis E. Effect of
  591 Linagliptin Versus Metformin on Glycemic Variability in Patients with Impaired Glucose Tolerance.
  592 Diabetes Technol Ther. 2017;19(8):471-5.
- 593 25. Gonzalez-Ortiz M, Martinez-Abundis E, Hernandez-Corona DM, Ramirez-Rodriguez AM. Effect
  594 of tadalafil administration on insulin secretion and insulin sensitivity in obese men. Acta Clin Belg.
  595 2017;72(5):326-30.
- 596 26. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of
- 597 liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with
  598 prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-409.
- 599 27. O'Neil PM, Garvey WT, Gonzalez-Campoy JM, Mora P, Ortiz RV, Guerrero G, et al. Effects of
  600 Liraglutide 3.0 Mg on Weight and Risk Factors in Hispanic Versus Non-Hipanic Populations: Subgroup
  601 Analysis from Scale Randomized Trials. Endocr Pract. 2016;22(11):1277-87.
- 602 28. Sanchez-Rodriguez MA, Zacarias-Flores M, Castrejon-Delgado L, Ruiz-Rodriguez AK, 603 Mandoza Nungz VM, Effects of Hormone Therapy on Oxidative Stress in Postmanopausal Women wi
- Mendoza-Nunez VM. Effects of Hormone Therapy on Oxidative Stress in Postmenopausal Women with
  Metabolic Syndrome. Int J Mol Sci. 2016;17(9).
- Sanchez-Munoz V, Salas-Romero R, Del Villar-Morales A, Martinez-Coria E, Pegueros-Perez A,
  Franco-Sanchez JG. [Decrease of liver fat content by aerobic exercise or metformin therapy in overweight
  or obese women]. Rev Invest Clin. 2013;65(4):307-17.
- 608 30. Gonzalez-Acevedo O, Hernandez-Sierra JF, Salazar-Martinez A, Mandeville PB, Valadez-
- 609 Castillo FJ, De La Cruz-Mendoza E, et al. [Effect of Omega 3 fatty acids on body female obese 610 composition]. Arch Latinoam Nutr. 2013;63(3):224-31.
- 611 31. Martínez-Abundis E, Valera-Gonzalez I, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of
  612 metformin and sibutramine on insulin sensitivity and adiposity in obese patients. Obesity and
  613 Metabolism. 2010;6:100-4.
- 614 32. Meaney E, Vela A, Samaniego V, Meaney A, Asbun J, Zempoalteca JC, et al. Metformin, arterial
  615 function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp
  616 Pharmacol Physiol. 2008;35(8):895-903.
- 617 33. Gonzalez-Ortiz M, Martinez-Abundis E, Kam-Ramos AM, Hernandez-Salazar E, Ramos-Zavala
- 618 MG. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.
- 619 Cardiovasc Drugs Ther. 2006;20(2):143-6.
- 34. Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, et al. X-PERT: weight reduction
  with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to
  treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7(6):699-708.
- 623 35. Zaragoza RM, Lonngi, G., Ortiz, R.A., Huerta, D.R. Comparison of two formulations of d-
- norpseudoephedrine and placebo in obese patients treated during six months [Comparación de dos
  formulaciones de d-norpseudoefedrina y placebo en pacientes obesos tratados durante seis meses]. Med
  Int Mex. 2001:17:260-71.
- 627 36. Cuellar GE, Ruiz AM, Monsalve MC, Berber A. Six-month treatment of obesity with sibutramine
- 628 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res.
- **629** 2000;8(1):71-82.

### Anti-obesity interventions in Mexican Population

630 37. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine 631 for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord. 2000;24(2):144-632 50. 633 38. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. Second phase of a double-blind study 634 clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after 635 treatment cross-over. Int J Obes Relat Metab Disord. 2001;25(5):741-7. 636 39. Ramos-Zavala MG, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, Gonzalez-637 Lopez R, Santiago-Hernandez NJ. Effect of diacerein on insulin secretion and metabolic control in drug-638 naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care. 2011;34(7):1591-4. 639 Fanghanel G, Silva U, Sanchez-Reyes L, Sisson D, Sotres D, Torres EM. Effects of metformin on 40. 640 fibrinogen levels in obese patients with type 2 diabetes. Rev Invest Clin. 1998;50(5):389-94. 641 41. Fanghanel G, Sanchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J. Metformin's effects on 642 glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care. 643 1996;19(11):1185-9. 644 Villar MM, Martinez-Abundis E, Preciado-Marquez RO, Gonzalez-Ortiz M. Effect of diacerein 42. 645 as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Arch 646 Endocrinol Metab. 2017;61(2):188-92. 647 43. A. H-B. Phentermine and topiramato vs phentermine plus placebo in patients with overweight or 648 obesity class I or II [Fentermina y topiramato contra fentermina más placebo en pacientes con sobrepeso u 649 obesidad clase I o II]. Med Int Mex. 2015;31:125-36. 650 Gonzalez-Ortiz M. Martinez-Abundis E. Grupo para el Tratamiento de la Diabetes Mellitus con 44. 651 C. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in 652 patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy]. Rev 653 Invest Clin. 2004;56(3):327-33. 654 Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, et al. Latin-American trial 45. 655 of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes 656 Metab. 2003;5(3):180-8. 657 46. Levva-Soto A, Chavez-Santoscov RA, Lara-Jacobo LR, Chavez-Santoscov AV, Gonzalez-658 Cobian LN. Daily Consumption of Chocolate Rich in Flavonoids Decreases Cellular Genotoxicity and 659 Improves Biochemical Parameters of Lipid and Glucose Metabolism. Molecules. 2018;23(9). 660 47. Padilla-Camberos E, Barragan-Alvarez CP, Diaz-Martinez NE, Rathod V, Flores-Fernandez JM. 661 Effects of Agave fructans (Agave tequilana Weber var. azul) on Body Fat and Serum Lipids in Obesity. 662 Plant Foods Hum Nutr. 2018:73(1):34-9. 663 Hernandez-Corona DM, Martinez-Abundis E, Gonzalez-Ortiz M. Effect of fucoidan 48. 664 administration on insulin secretion and insulin resistance in overweight or obese adults. J Med Food. 665 2014;17(7):830-2. 666 Martinez-Abundis E, Gonzalez-Ortiz M, Mercado-Sesma AR, Reynoso-von-Drateln C, Moreno-49. 667 Andrade A. Effect of avocado soybean unsaponifiables on insulin secretion and insulin sensitivity in

- patients with obesity. Obes Facts. 2013;6(5):443-8.
- 669 50. Tovar AR, Caamano Mdel C, Garcia-Padilla S, Garcia OP, Duarte MA, Rosado JL. The inclusion
- of a partial meal replacement with or without inulin to a calorie restricted diet contributes to reach
  recommended intakes of micronutrients and decrease plasma triglycerides: a randomized clinical trial in
  obese Mexican women. Nutr J. 2012;11:44.
- 673 51. Rosado JL, Garcia OP, Ronquillo D, Hervert-Hernandez D, Caamano Mdel C, Martinez G, et al.
- 674 Intake of milk with added micronutrients increases the effectiveness of an energy-restricted diet to reduce
- 675 body weight: a randomized controlled clinical trial in Mexican women. J Am Diet Assoc.
- 676 2011;111(10):1507-16.
- 677 52. Hernandez-Gonzalez SO, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA.
- 678 Chitosan improves insulin sensitivity as determined by the euglycemic-hyperinsulinemic clamp technique 679 in obese subjects. Nutr Res. 2010;30(6):392-5.

### Anti-obesity interventions in Mexican Population

- 680 53. Ble-Castillo JL, Aparicio-Trapala MA, Francisco-Luria MU, Cordova-Uscanga R, Rodriguez-681 Hernandez A, Mendez JD, et al. Effects of native banana starch supplementation on body weight and 682 insulin sensitivity in obese type 2 diabetics. Int J Environ Res Public Health. 2010;7(5):1953-62. 683 54. Gomez-Garcia A, Hernandez-Salazar E, Gonzalez-Ortiz M, Martinez-Abundis E. [Effect of oral 684 zinc administration on insulin sensitivity, leptin and androgens in obese males]. Rev Med Chil. 685 2006;134(3):279-84. 686 55. Campos-Nonato I, Hernandez L, Barquera S. Effect of a High-Protein Diet versus Standard-687 Protein Diet on Weight Loss and Biomarkers of Metabolic Syndrome: A Randomized Clinical Trial. Obes 688 Facts. 2017;10(3):238-51. 689 de Jesus Romero-Prado MM, Curiel-Beltran JA, Miramontes-Espino MV, Cardona-Munoz EG, 56. 690 Rios-Arellano A, Balam-Salazar LB, Dietary flavonoids added to pharmacological antihypertensive 691 therapy are effective in improving blood pressure. Basic Clin Pharmacol Toxicol. 2015;117(1):57-64. 692 Rodriguez-Hernandez H, Cervantes-Huerta M, Rodriguez-Moran M, Guerrero-Romero F. 57. 693 Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of 694 type of diet. Ann Hepatol. 2011;10(4):486-92. 695 Madero M, Arriaga JC, Jalal D, Rivard C, McFann K, Perez-Mendez O, et al. The effect of two 58. 696 energy-restricted diets, a low-fructose diet versus a moderate natural fructose diet, on weight loss and 697 metabolic syndrome parameters: a randomized controlled trial. Metabolism. 2011:60(11):1551-9. 698 Perichart-Perera O, Balas-Nakash M, Munoz-Manrique C, Legorreta-Legorreta J, Rodriguez-59. 699 Cano A, Mier-Cabrera J, et al. Structured hypocaloric diet is more effective than behavioral therapy in 700 reducing metabolic syndrome in Mexican postmenopausal women: a randomized controlled trial. 701 Menopause. 2014;21(7):711-20. 702 60. Macias-Cervantes MH, Rodriguez-Soto JM, Uribarri J, Diaz-Cisneros FJ, Cai W, Garay-Sevilla 703 ME. Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in 704 adult overweight men. Nutrition. 2015;31(3):446-51. 705 Rodriguez-Hernandez H, Morales-Amaya UA, Rosales-Valdez R, Rivera-Hinojosa F, Rodriguez-61. 706 Moran M, Guerrero-Romero F. Adding cognitive behavioural treatment to either low-carbohydrate or 707 low-fat diets: differential short-term effects. Br J Nutr. 2009;102(12):1847-53. 708 Moran S, Uribe M, Prado ME, de la Mora G, Munoz RM, Perez MF, et al. [Effects of fiber 62. 709 administration in the prevention of gallstones in obese patients on a reducing diet. A clinical trial]. Rev 710 Gastroenterol Mex. 1997;62(4):266-72. 711 Garcia-Vivas JM, Galaviz-Hernandez C, Becerril-Chavez F, Lozano-Rodriguez F, Zamorano-63. 712 Carrillo A, Lopez-Camarillo C, et al. Acupoint catgut embedding therapy with moxibustion reduces the 713 risk of diabetes in obese women. J Res Med Sci. 2014;19(7):610-6. 714 Hernandez-Lepe MA, Wall-Medrano A, Lopez-Diaz JA, Juarez-Oropeza MA, Hernandez-Torres 64. 715 RP, Ramos-Jimenez A. Hypolipidemic Effect of Arthrospira (Spirulina) maxima Supplementation and a 716 Systematic Physical Exercise Program in Overweight and Obese Men: A Double-Blind, Randomized, and 717 Crossover Controlled Trial. Mar Drugs. 2019;17(5). 718 Alvarado-Reynoso B, Ambriz-Tututi M. Effects of repetitive transcranial magnetic stimulation in 65. 719 combination with a low-carbohydrate diet in overweight or obese patients. A randomized controlled trial. 720 Obesity Medicine, 2019;14:100095. 721 Zarate X, Arceo-Olaiz R, Montalvo Hernandez J, Garcia-Garcia E, Pablo Pantoja J, Herrera MF. 66. 722 Long-term results of a randomized trial comparing banded versus standard laparoscopic Roux-en-Y 723 gastric bypass. Surg Obes Relat Dis. 2013;9(3):395-7. 724 Arceo-Olaiz R, Espana-Gomez MN, Montalvo-Hernandez J, Velazquez-Fernandez D, Pantoja JP, 67. 725 Herrera MF. Maximal weight loss after banded and unbanded laparoscopic Roux-en-Y gastric bypass: a 726 randomized controlled trial. Surg Obes Relat Dis. 2008;4(4):507-11. 727 Robles-Cervantes JA, Martinez-Abundis E, Gonzalez-Ortiz M, Cardenas-Camarena L, 68. 728 Hernandez-Salazar E, Olvera-Ozuna R. Behavior of insulin sensitivity and its relation to leptin and tumor 729 necrosis factor-alpha in obese women undergoing liposuction: 6-month follow-up. Obes Surg.
- **730** 2007;17(9):1242-7.

### Anti-obesity interventions in Mexican Population

- 731 69. Hernandez-Cordero S, Barquera S, Rodriguez-Ramirez S, Villanueva-Borbolla MA, Gonzalez de 732 Cossio T, Dommarco JR, et al. Substituting water for sugar-sweetened beverages reduces circulating 733 triglycerides and the prevalence of metabolic syndrome in obese but not in overweight Mexican women 734 in a randomized controlled trial. J Nutr. 2014;144(11):1742-52. 735 Cantrell L. Redotex(R) revisited: intentional overdose with an illegal weight loss product. J 70. Emerg Med. 2012;43(2):e147-8. 736 737 71. The effects of nonpharmacologic interventions on blood pressure of persons with high normal 738 levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA. 1992;267(9):1213-20. 739 72. Loya JC. Systematic Review of Physical Activity Interventions in Hispanic Adults. Hisp Health 740 Care Int. 2018;16(4):174-88. 741 73. Brown SA, Garcia AA, Kouzekanani K, Hanis CL. Culturally competent diabetes self-742 management education for Mexican Americans: the Starr County border health initiative. Diabetes Care. 743 2002;25(2):259-68. 744 Williams G. Withdrawal of sibutramine in Europe. BMJ. 2010;340:c824. 74. 745 75. Curfman GD, Morrissey S, Drazen JM. Sibutramine--another flawed diet pill. N Engl J Med. 746 2010;363(10):972-4. 747 Peterli R, Wolnerhanssen BK, Peters T, Vetter D, Kroll D, Borbely Y, et al. Effect of 76. 748 Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients 749 With Morbid Obesity: The SM-BOSS Randomized Clinical Trial, JAMA, 2018;319(3):255-65. 750 77. Buchwald H, Buchwald JN, McGlennon TW. Systematic review and meta-analysis of medium-751 term outcomes after banded Roux-en-Y gastric bypass. Obes Surg. 2014;24(9):1536-51. 752 Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N 78. 753 Engl J Med. 2017;376(15):1492. 754 Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, et al. The utility of weight 79. 755 loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study. 756 Surg Obes Relat Dis. 2017;13(3):491-500. 757 Promotion OoDPaH. Overweight and Obesity 2020 [January 11, 2021]. Available from: 80. 758 https://health.gov/healthypeople/objectives-and-data/browse-objectives/overweight-and-obesity. 759 Agency USEP. What is Border 2020? 2020 [updated September 1, 2020January 4, 2021]. 81. 760 Available from: https://www.epa.gov/usmexicoborder/what-border-2020. 761 82. Services USDoHH. U.S.-Mexico Border Health Commission 2020 [Available from: 762 https://www.hhs.gov/about/agencies/oga/about-oga/what-we-do/international-relations-
- 763 division/americas/border-health-commission/index.html.

#### Anti-obesity interventions in Mexican Population

**766** Figure Legends

767

**768** Figure 1. Height measurement standing up, sitting and the lower body segment. From North to South the

height is lower at expenses to the lower segment of the body (p < 0.0001 adjusted by Bonferroni for all

regions). The sitting height reflects the upper segment body and shows small differences between regions.

771 Mean and standard deviations. Data obtained from the ENEC 1993. CDMX: Mexico City, Sitting: sitting

- height, Lower: Lower segment of the body (Height-sitting height).
- 773

Figure 2. Procedure of the study. The flowchart shows the processes of collection, screening, qualityassessment data extraction and analysis.

776

777Figure 3. Pooled analysis of weighted size of effect by Cohen-d in BMI loss with nutritional and behavior

interventions. The analysis was stratified by placebo or active comparator. LFDT: Low fat diet, LCD:

779 Low carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical activity, Dark Choc: Dark

780 chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet, WEP: Water and Education

781 Provision, LFM: Low fat milk, Micronut: Micronutrients, PMR: Partial meal replacement, AntiBP:

- 782 Antihypertensive medication. REML: Restricted maximum likelihood.
- 783

Figure 4. Pooled analysis of weighted size of effect by Cohen-d in waist circumference with nutritional
and behavior interventions. The analysis was stratified by placebo or active comparator. LFDT: Low fat
diet, LCD: Low carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical activity, Dark
Choc: Dark chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet, LFM: Low fat

788 milk, Micronut: Micronutrients, PMR: Partial meal replacement. REML: Restricted maximum likelihood.789

Figure 5. Pooled analysis of weighted size of effect by Cohen-d in triglycerides serum concentration with

nutritional and behavior interventions. The analysis was stratified by placebo or active comparator.

T92 LFDT: Low fat diet, LCD: Low carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical

793 activity, Dark Choc: Dark chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet,

794 WEP: Water and Education Provision, LFM: Low fat milk, Micronut: Micronutrients, PMR: Partial meal

replacement, AntiBP: Antihypertensive medication. REML: Restricted maximum likelihood.

Figure 6. Pooled analysis of weighted size of effect by Cohen-d in systolic blood pressure with nutritional

and behavior interventions. The analysis was stratified by placebo or active comparator. LCD: Low

799 carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical activity, Dark Choc: Dark

800 chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet, WEP: Water and Education

801 Provision, LFM: Low fat milk, Micronut: Micronutrients, AntiBP: Antihypertensive medication. REML:

802 Restricted maximum likelihood.

803 Figure 7. Pooled analysis of weighted size of effect by Cohen-d in BMI loss with drug (medication)

treatment. The analysis was stratified by T2D status. The Form1 and Form2 are described in the text, they

are not approved by FDA. Met: Merformin, Sibut: Sibutramine, DHA: Docosahexaenoic acid, EPA:

806 Eicosapentanoic acid, Orlit: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top: Topiramate. REML:

807 Restricted maximum likelihood.

(medication) treatment. The analysis was stratified by T2D status. The Form1 and Form2 are described in

the text, they are not approved by FDA. Met: Merformin, Sibut: Sibutramine, DHA: Docosahexaenoic

Figure 8. Pooled analysis of weighted size of effect by Cohen-d in waist circumference with drug

### Anti-obesity interventions in Mexican Population


- 812 acid, EPA: Eicosapentanoic acid, Orlit: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top: 813 Topiramate. REML: Restricted maximum likelihood. 814 815 Figure 9. Pooled analysis of weighted size of effect by Cohen-d in glucose serum concentration with drug 816 (medication) treatment. The analysis was stratified by T2D status. Met: Merformin, Orlit: Orlistat, Glim: 817 Glimepiride, Phent: Phentermine, Top: Topiramate. REML: Restricted maximum likelihood. 818 819 Figure 10. Pooled analysis of weighted size of effect by Cohen-d in diastolic blood pressure with drug 820 (medication) treatment. The analysis was stratified by T2D status. The Form1 and Form2 are described in the text, they are not approved by FDA. Met: Merformin, Sibut: Sibutramine, Orlit: Orlistat, Glim: 821 822 Glimepiride, Phent: Phentermine, Top: Topiramate. REML: Restricted maximum likelihood. 823 824 Supplemental Figure 1. Meta regression of medication mean difference effects on HDL-C (upper panel) 825 and triglycerides (lower panel) concentrations, adjusted by mean age, BMI, duration of treatment 826 (months), geographical latitude and use of placebo or active comparator. The grey zone represents the 827 95% CI of the regression. Liraglutide was used in the highest obesity and geographical sites at North. The 828 Form1 and Form2 are described in the text, they are not approved by FDA. Met: Merformin, Sibut: 829 Sibutramine, Orlit: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top: Topiramate. 830 831 Supplemental Figure 2. Meta regression of medication mean difference effects on diastolic blood pressure 832 adjusted by mean age, BMI, duration of treatment (months), geographical latitude and use of placebo or 833 active comparator. The upper panel shows the effect of BMI and the lower panel the geographical 834 location. The grey zone represents the 95% CI of the regression. Liraglutide was used in the highest 835 obesity and geographical sites at North. The Form1 and Form2 are described in the text, they are not 836 approved by FDA. Met: Merformin, Sibut: Sibutramine, Orlit: Orlistat, Glim: Glimepiride, Phent: 837 Phentermine, Top: Topiramate. 838 839 Supplemental figure 3. Network meta-analysis of the studies examining the efficacy of drug treatments in 840 patients with obesity in (A) BMI in non-diabetic patients compared to placebo, (B) BMI in patients with 841 diabetes compared to metformin. The colors of edges and nodes refer to the risk of bias: low (green), 842 moderate (yellow), and high (red). The dosage of DHA and EPA are in mg per day. Met: Metformin. 843 Diac+Met: Diacerin + Metformin. The Form1 and Form2 are described in the text, they are not approved 844 by FDA. Plc: Placebo. 845
- 846

809


810

811

#### Anti-obesity interventions in Mexican Population



#### Anti-obesity interventions in Mexican Population



### Anti-obesity interventions in Mexican Population

		Nut	rition	Be	haviou	ır: BN	/I Cohen-d		
		Treatme	ent		Contr			Cohen's d	Weight
Study	N	Mean	SD	Ν	Mean	SD		with 95% CI	(%)
Active comp									
Rodriguez 2009 (LFDt+CBT)	28	32	3.7	29	34.6	5.2		-0.57 [ -1.10, -0.04]	5.63
Rodriguez 2009 (LCD+CBT)	24	33.3	4.3	21	34.9	4		-0.38 [ -0.98, 0.21]	5.05
Rodriguez 2011 (LCD)	28	36.7	6.8	26	34.8	6.3		0.29 [ -0.25, 0.83]	5.56
Macias 2014 (Phys Act)	14	27.7	2	14	28.3	1.9		-0.31 [ -1.05, 0.44]	3.86
Macias 2014 (Phys Act+AGE's)	15	27.7	1.72	14	28.3	1.9		-0.33 [ -1.07, 0.40]	3.93
Perichart 2014 (CBT+Hipocal)	55	29.96	4.27	63	31.37	4.17	-	-0.33 [ -0.70, 0.03]	7.49
Hernandez 2014 (WEP)	102	30.05	3.7	87	30.7	3.7	-	-0.18 [ -0.46, 0.11]	8.44
Leyva 2018 (Dark Choc)	42	30.1	2.2	42	32.4	2.5		-0.98 [ -1.43, -0.52]	6.45
Padilla 2018 (Fructans)	14		8.59	14	35	8.59		-0.23 [ -0.98, 0.51]	3.87
Heterogeneity: $\tau^2 = 0.06$ , $I^2 = 49.83\%$	6, H <sup>2</sup>	= 1.99					•	-0.34 [ -0.58, -0.10]	
Test of $\theta_i = \theta_j$ : Q(8) = 15.00, p = 0.06	5								
Placebo comp									
Rosado 2011 (LFM )	33	33.2	3.12	31	32.3	3.4		0.28 [ -0.22, 0.77]	6.01
Rosado 2011 (LFM+Micronut)	37	32.7	4.9	31	32.3	3.4	-	0.09 [ -0.38, 0.57]	6.17
Hernandez 2010 (Chitosan)	6	31.6	2.2	6	31.8	2.1		-0.09 [ -1.23, 1.04]	2.10
Tovar 2012 (PMR)	28	29.38	3.49	29	30.06	3.8		-0.19 [ -0.71, 0.33]	5.72
Tovar 2012 (PMR+Inulin)	23	30.46	3.69	29	30.06	3.8		0.11 [ -0.44, 0.65]	5.45
Tovar 2012 (Inulin)	30	29.99	4.66	29	30.06	3.8		-0.02 [ -0.53, 0.49]	5.83
Martinez 2013 (Avocat-oil bean)	7	35.2	2.8	7	33.8	2.8		0.50 [ -0.56, 1.56]	2.32
Hernandez 2014 (Fucoidan)	11	29.5	2.3	8	32.9	1.9		-1.59 [ -2.63, -0.54]	2.40
Romero 2015 (Flavonoids+AntiBP)	40	28.3	3.6	39	29.9	3		-0.48 [ -0.93, -0.03]	6.51
Campos 2017 (High Protein Diet)	59	31.8	4	46	30.8	4	-	0.25 [ -0.14, 0.64]	7.21
Heterogeneity: $\tau^2 = 0.06$ , $I^2 = 40.87\%$	6, H <sup>2</sup> :	= 1.69					•	-0.04 [ -0.28, 0.19]	
Test of $\theta_i = \theta_j$ : Q(9) = 17.80, p = 0.04	ļ								
Overall							•	-0.20 [ -0.38, -0.01]	
Heterogeneity: $\tau^2 = 0.08$ , $I^2 = 54.40\%$	6, H <sup>2</sup>	= 2.19							
Test of $\theta_i = \theta_j$ : Q(18) = 39.50, p = 0.0									
Test of group differences: $Q_b(1) = 3.0$	04, p	= 0.08				r		_	
						_4	4 -2 0	2	
Random-effects REML model									

# Nutrition/Bobaviour: BMI Cohon d

Random-effects REML model 855

856 Figure 3.

### Anti-obesity interventions in Mexican Population

	Г	uunuo	n/Be	nav	iour: v	vaist (	circum Conen-d		
		Treatme			Contro	and the second second		Cohen's d	Weigh
Study	N	Mean	SD	N	Mean	SD		with 95% CI	(%)
Active comp									
Rodriguez 2009 (LCD+CBT)	24	98.7	10.8	21	108.8	11.8		-0.90 [ -1.51, -0.28]	7.18
Rodriguez 2009 (LFDt+CBT)	28	100.4	8.8	29	102.7	10.6		-0.24 [ -0.76, 0.29]	8.07
Hernandez 2014 (WEP)	102	91.3	3.02	87	91.3	3.02		0.00 [ -0.29, 0.29]	10.40
Macias 2014 (Phys Act)	14	97.3	5.1	14	99.1	6.6		-0.31 [ -1.05, 0.44]	6.05
Perichart 2014 (CBT+Hipocal)	55	98.19	9.74	63	101.87	90.9		-0.06 [ -0.42, 0.31]	9.68
Macias 2014 (Phys Act+AGE's)	15	97.4	6.6	14	99.1	6.6		-0.26 [ -0.99, 0.47]	6.16
Padilla 2018 (Fructans)	14	111	5	14	111	6		0.00 [ -0.74, 0.74]	6.09
Leyva 2018 (Dark Choc)	42	90.4	4.5	42	94.9	3.9		-1.07 [ -1.53, -0.61]	8.72
Heterogeneity: $\tau^2 = 0.12$ , $I^2 = 65.92$	%, H <sup>2</sup> :	= 2.93					•	-0.34 [ -0.65, -0.04]	
Test of $\theta_i = \theta_j$ : Q(7) = 21.02, p = 0.0	00								
Placebo comp									
Rosado 2011 (LFM)	33	96.1	7.8	31	96.5	7.7		-0.05 [ -0.54, 0.44]	8.38
Rosado 2011 (LFM+Micronut)	37	95.9	12.4	31	96.5	7.7		-0.06 [ -0.53, 0.42]	8.51
Hernandez 2010 (Chitosan)	6	99	9	6	100	6		-0.13 [ -1.26, 1.00]	3.68
Martinez 2013 (Avocat-oil bean)	7	111	5	7	105	11		0.70 [ -0.38, 1.78]	3.93
Hernandez 2014 (Fucoidan)	11	93.25	4.6	8	107.2	8.75		-2.10 [ -3.23, -0.97]	3.70
Campos 2017 (High Protein Diet)	59	98.5	14.4	46	96.8	14.5	-	0.12 [ -0.27, 0.50]	9.44
Heterogeneity: $\tau^2 = 0.43$ , $I^2 = 80.89$	%, H <sup>2</sup> :	= 5.23					-	-0.19 [ -0.80, 0.42]	
Test of $\theta_i = \theta_j$ : Q(5) = 15.30, p = 0.0	)1								
Overall							•	-0.27 [ -0.53, -0.01]	
Heterogeneity: $\tau^2 = 0.15$ , $I^2 = 67.98$	%, H <sup>2</sup> :	= 3.12							
Test of $\theta_i = \theta_j$ : Q(13) = 38.59, p = 0.	.00								
Test of group differences: $Q_b(1) = 0$	.20, p	= 0.66					·	-	
Random-effects REML model						-	4 -2 0	2	

#### Nutrition/Behaviour: Waist circum Cohen-d

858 Random-ef 859 Figure 4.

860

### Anti-obesity interventions in Mexican Population

				ena			des difference		loop Diff		Moight
Study	N	Treatme Mean	SD	N	Contr Mean	SD			Aean Diff. ith 95% C		Weight (%)
Active comp											()
Rodriguez 2009 (LCD+CBT)	24	123.1	43.1	21	142.3	63.9		-19.20 [	-50.70,	12.30]	6.01
Rodriguez 2009 (LFDt+CBT)	28	134.3	56.2	29	189.3	86.8		-55.00 [	-93.11,	-16.89]	5.19
Rodriguez 2011 (LCD)	28	173.5	63.9	26	155	53.8		18.50 [	-13.13,	50.13]	5.99
Macias 2014 (Phys Act+AGE's)	15	132	46.1	14	158.5	75.3		-26.50 [	-71.59,	18.59]	4.43
Perichart 2014 (CBT+Hipocal)	55	180.76	76.2	63	170.9	51.8		9.86 [	-13.40,	33.12]	7.11
Hernandez 2014 (WEP)	102	149	28.27	87	161	27.87		-12.00 [	-20.03,	-3.97]	8.83
Aacias 2014 (Phys Act)	14	113.36	91.2	14	158.5	75.3		-45.14 [	-107.09,	16.81]	3.04
_eyva 2018 (Dark Choc )	42	153.26	18.95	42	224.1	23.1		-70.84 [	-79.88,	-61.80]	8.75
Padilla 2018 (Fructans)	14	107.9	51.03	14	165.6	232.52		-57.70 [	-182.40,	67.00]	1.00
leterogeneity: r <sup>2</sup> = 860.84, l <sup>2</sup> = 89.73	3%, H <sup>2</sup>	= 9.73					•	-25.16 [	-48.06,	-2.26]	
Test of $\theta_i = \theta_j$ : Q(8) = 119.22, p = 0.00	)										
'lacebo comp											
lernandez 2010 (Chitosan)	6	141.59	79.65	6	168.19	53.1		-26.60 [	-103.20,	50.00]	2.25
Rosado 2011 (LFM)	33	143.1	51	31	136.7	50.4		6.40 [	-18.46,	31.26]	6.90
Rosado 2011 (LFM+Micronut)	37	136.1	50.5	31	136.7	50.4		-0.60 [	-24.68,	23.48]	7.00
Fovar 2012 (PMR)	28	124.9	55	29	133.4	47.2		-8.50 [	-35.08,	18.08]	6.67
ovar 2012 (Inulin)	30	131.6	57.2	29	133.4	47.2	-	-1.80 [	-28.61,	25.01]	6.63
Fovar 2012 (PMR+Inulin)	23	135.5	49.6	29	133.4	47.2		2.10 [	-24.32,	28.52]	6.69
lernandez 2014 (Fucoidan)	11	185.99	151	8	159.5	67		- 26.49 [	-86.01,	138.99]	1.20
Romero 2015 (Flavonoids+AntiBP)	40	99	47	39	113.6	62		-14.60 [	-38.82,	9.62]	6.98
Campos 2017 (High Protein Diet)	59	119	101.3	46	135.8	88.3		-16.80 [	-53.75,	20.15]	5.33
leterogeneity: $\tau^2 = 0.00$ , $I^2 = 0.00\%$ ,	$H^2 = 1$	.00					•	-4.07 [	-13.94,	5.79]	
Test of $\theta_i = \theta_j$ : Q(8) = 2.90, p = 0.94											
Overall							•	-14.92 [	-28.14,	-1.70]	
leterogeneity: τ <sup>2</sup> = 498.58, Ι <sup>2</sup> = 79.24	1%, H <sup>2</sup>	= 4.82									
First of $\theta_i = \theta_j$ : Q(17) = 147.85, p = 0.0	00										
Test of group differences: $Q_b(1) = 2.7$	5, p =	0.10				_		_			
andom-effects REML model						-200	) -100 0 100				

#### Nutrition/Behaviour: Triglycerides difference

861 Random-effects REML model

862 Figure 5.

### Anti-obesity interventions in Mexican Population

	1	Nutritio	n/Be	hav	iour: S	systolic	BP Cohen-d		
		Treatme	nt		Contro	ol		Cohen's d	Weight
Study	N	Mean	SD	Ν	Mean	SD		with 95% CI	(%)
Active comp									
Rodriguez 2011 (LCD)	28	120.4	9.1	26	117.1	16.6		0.25 [ -0.29, 0.78]	8.94
Hernandez 2014 (WEP)	102	98	3.02	87	98.6	4.03		-0.17 [ -0.46, 0.12]	11.73
Macias 2014 (Phys Act+AGE's)	15	126.3	13.7	14	123.3	12.5		0.23 [ -0.50, 0.96]	6.95
Macias 2014 (Phys Act)	14	122.8	13.4	14	123.3	12.5		-0.04 [ -0.78, 0.70]	6.85
Perichart 2014 (CBT+Hipocal)	55	119.27	12.7	63	122.68	14.76		-0.25 [ -0.61, 0.12]	10.90
Leyva 2018 (Dark Choc)	42	127.8	11.2	42	133.9	12.7		-0.51 [ -0.94, -0.07]	10.09
Heterogeneity: $r^2 = 0.00$ , $I^2 = 0.00\%$ ,	$H^{2} = 1$	.00					•	-0.17 [ -0.34, 0.01]	
Test of $\theta_i = \theta_j$ : Q(5) = 6.13, p = 0.29									
Placebo comp									
Rosado 2011 (LFM+Micronut)	37	121.7	7.1	31	126	7.1		-0.61 [ -1.09, -0.12]	9.48
Rosado 2011 (LFM)	33	128.1	7.1	31	126	7.1		0.30 [ -0.20, 0.79]	9.42
Hernandez 2014 (Fucoidan)	11	112.4	12.9	8	116.1	10.2		-0.31 [ -1.23, 0.60]	5.44
Romero 2015 (Flavonoids+AntiBP)	40	120.7	4.3	39	125.7	3.9		-1.22 [ -1.70, -0.74]	9.56
Campos 2017 (High Protein Diet)	59	122.5	17	46	120	16.8		0.15 [ -0.24, 0.53]	10.64
Heterogeneity: $\tau^2 = 0.34$ , $I^2 = 83.53\%$	$H^{2} =$	6.07						-0.33 [ -0.90, 0.23]	
Test of $\theta_i = \theta_j$ : Q(4) = 26.30, p = 0.00									
Overall								-0.21 [ -0.49, 0.07]	
Heterogeneity: $\tau^2 = 0.15$ , $I^2 = 72.58\%$	$H^2 = 3$	3.65							
Test of $\theta_i = \theta_j$ : Q(10) = 33.16, p = 0.0	0								
Test of group differences: $Q_b(1) = 0.3$	80, p =	0.58					r	٦	
Random-effects REML model						-	2 -1 0	1	

#### 864 Random-eff 865 Figure 6.

### 866

#### Nutrition/Behaviour: Systolic BP Cohen-d

### Anti-obesity interventions in Mexican Population

		Ν	Nedic	atio	n: BM	I Coh	nen-d		
	-	Treatme	ent		Contro	d.	Cohen's	s d	Weight
Study	Ν	Mean	SD	Ν	Mean	SD	with 95%	6 CI	(%)
No T2D									
Morin 2001 (Form2)	51	30.95	4.8	26	35.6	5.19	-0.94 [ -1.44	, -0.45]	6.69
Morin 2001 (Form1)	59	30.88	4.8	26	35.6	5.19	-0.96 [ -1.44	, -0.48]	6.80
Gonzalez 2006 (Ezetimibe)	6	28.8	2.3	6	29.4	2	-0.28 [ -1.42	, 0.86]	2.83
Meaney 2008 (Met+Diet)	22	33	4.6	17	32.2	4.3	0.18 [ -0.46	, 0.81]	5.56
Martinez 2010 (Sibut+Met)	9	31.7	3.1	9	30.8	2.7	0.31 [ -0.62	, 1.24]	3.71
Gonzalez 2013 (DHA 940 +EPA 1160)	20	33.6	4.57	20	37.68	4.98	-0.85 [ -1.50	, -0.21]	5.46
Gonzalez 2013 (DHA 470 +EPA 580 )	20	33.93	3.9	20	37.68	4.98	-0.84 [ -1.48	, -0.19]	5.47
Le Roux 2017 (Liraglutide)	783	36.6	2.9	327	38.3	2.6	-0.60 [ -0.74	, -0.47]	9.51
O´neil 2017 (Liraglutide)	339	34.8	5.65	189	36.47	6.1	-0.29 [ -0.47	, -0.11]	9.26
Heterogeneity: $\tau^2 = 0.09$ , $I^2 = 74.26\%$ , $H^2$	= 3.88	3					-0.53 [ -0.80	, -0.27]	
Test of $\theta_i = \theta_j$ : Q(8) = 23.90, p = 0.00									
T2D									
Halpern 2003 (Orlt)	139	32.9	.85	141	33.5	.9		, -0.44]	8.84
Gonzalez 2004 (Met)	33	30.1	4.2	37	31.4	8.5	-0.19 [ -0.66	, 0.28]	6.91
Gonzalez 2004 (Glim+Met )	34	31.8	5	37	31.4	8.5	0.06 [ -0.41	, 0.52]	6.95
Hernandez 2015 (Phen 7.5+Top 50)	29	30.1	2.9	29	29.7	2.7	0.14 [ -0.37	, 0.66]	6.52
Hernandez 2015 (Phent 15+Top 100)	29	26.8	2.9	29	29.7	2.7	-1.04 [ -1.58	, <mark>-0.4</mark> 9]	6.25
Hernandez 2015 (Phent 30 + Plc)	26	30.12	1.6	29	29.7	2.7	0.19 [ -0.34	, 0.72]	6.39
Mendez 2017 (Met+Diacerein)	6	32.1	3.7	6	31.7	2	0.13 [ -1.00	, 1.27]	2.85
Heterogeneity: $r^2 = 0.17$ , $I^2 = 74.94\%$ , $H^2$	= 3.99	9					-0.24 [ -0.61	, 0.13]	
Test of $\theta_i = \theta_j$ : Q(6) = 24.78, p = 0.00									
Overall							-0.40 [ -0.63	, -0.17]	
Heterogeneity: $r^2 = 0.14$ , $I^2 = 79.59\%$ , $H^2$	= 4.90	0							
Test of $\theta_i = \theta_j$ : Q(15) = 50.59, p = 0.00									
Test of group differences: $Q_b(1) = 1.60$ , p	= 0.2	1							
						-	2 -1 0 1		
Random-effects REML model									

868 Figure 7.

869

## Anti-obesity interventions in Mexican Population

		Med	licatio	n: W	aist ci	rcum	Cohen-d		
		Treatme	ent		Contro	l		Cohen's d	Weight
Study	N	Mean	SD	N	Mean	SD		with 95% CI	(%)
No T2D									
Morin 2001 (Form2)	51	97.25	11.5	26	106.4	11.5		-0.80 [ -1.28, -0.31]	12.79
Morin 2001 (Form1)	59	93.4	11.95	26	106.4	11.5		-1.10 [ -1.59, -0.61]	12.77
Meaney 2008 (Met+Diet)	22	101.8	11.7	17	98.7	11.3		0.27 [ -0.37, 0.90]	11.41
Gonzalez 2013 (DHA 470 +EPA 580 )	20	94.61	1.01	20	104	8.89		-1.48 [ -2.18, -0.78]	10.81
O'neil 2017 (Liraglutide)	339	105.8	13	189	104.2	14		0.12 [ -0.06, 0.30]	15.06
Le Roux 2017 (Liraglutide)	783	109.6	8.3	327	113.3	7.3		-0.46 [ -0.59, -0.33]	15.25
Heterogeneity: $r^2 = 0.37$ , $I^2 = 94.39\%$ , H	$H^2 = 17$	7.83						-0.55 [ -1.07, -0.03]	
Test of $\theta_i = \theta_j$ : Q(5) = 55.22, p = 0.00									
T2D									
Halpern 2003 (Orlt)	139	102.2	5.3	141	105.2	5.4	-	-0.56 [ -0.80, -0.32]	14.74
Mendez 2017 (Met+Diacerein)	6	106.2	11.4	6	101.7	8.4		0.45 [ -0.70, 1.60]	7.17
Heterogeneity: $\tau^2 = 0.33$ , $I^2 = 65.05\%$ , H	$+^2 = 2.$	86						-0.22 [ -1.16, 0.72]	
Test of $\theta_i = \theta_j$ : Q(1) = 2.86, p = 0.09									
Overall							•	-0.47 [ -0.89, -0.06]	
Heterogeneity: $\tau^2 = 0.30$ , $I^2 = 92.99\%$ , H	$+^2 = 14$	1.27							
Test of $\theta_i = \theta_j$ : Q(7) = 60.30, p = 0.00									
Test of group differences: $Q_b(1) = 0.37$ ,	p = 0.	54							
							-2 -1 0 1	2	
Random-effects REML model									

870 Random-eff 871 Figure 8.

872

## Anti-obesity interventions in Mexican Population

		M	edica	tion:	Gluco	ose Co	hen-d				
		Treatme	ent		Contro	l			Cohen's d		Weight
Study	Ν	Mean	SD	Ν	Mean	SD			with 95% C	1	(%)
No T2D											
Gonzalez 2006 (Ezetimibe)	6	95.4	10.8	6	99	7.2			0.39 [ -1.53, 0	0.75]	8.89
Meaney 2008 (Met+Diet)	22	99	13.2	17	102.6	11.3			-0.29 [ -0.93,	0.35]	9.88
Le Roux 2017 (Liraglutide)	783	92.7	12.24	327	99.9	10.8			-0.61 [ -0.74, -	0.48]	10.38
O'neil 2017 (Liraglutide)	339	89.6	10.1	189	88.2	9.3			0.14 [ -0.04,	0.32]	10.36
Heterogeneity: $\tau^2 = 0.13$ , $I^2 = 88.62\%$ , H	<sup>2</sup> = 8.7	9						•	-0.26 [ -0.70,	0.17]	
Test of $\theta_i = \theta_j$ : Q(3) = 44.22, p = 0.00											
T2D											
Halpern 2003 (Orlt)	139	180.9	6.12	141	206.9	5.4	-		-4.51 [ -4.95, -4	4.07]	10.14
Gonzalez 2004 (Glim+Met )	34	178.2	58.8	37	173.3	57.5		-	0.08 [ -0.38,	0.55]	10.11
Gonzalez 2004 (Met)	33	188	48.6	37	173.3	57.5		-	- 0.27 [ -0.20,	0.75]	10.11
Hernandez 2015 (Phent 30 + Plc)	26	90.23	15.73	29	91.74	14.52			-0.10 [ -0.63,	0.43]	10.03
Hernandez 2015 (Phen 7.5+Top 50)	29	94.03	15.73	29	91.74	14.52		-	- 0.15 [ -0.36, 0	0.67]	10.05
Hernandez 2015 (Phent 15+Top 100)	29	89.96	15.73	29	91.74	14.52			-0.12 [ -0.63,	0.40]	10.05
Heterogeneity: $\tau^2$ = 3.45, $I^2$ = 98.24%, H	<sup>2</sup> = 56.	86							-0.70 [ -2.21,	0.80]	
Test of $\theta_i = \theta_j$ : Q(5) = 331.79, p = 0.00											
Overall								-	-0.54 [ -1.43,	0.35]	
Heterogeneity: $\tau^2$ = 2.00, $I^2$ = 98.56%, H	<sup>2</sup> = 69.	41									
Test of $\theta_i = \theta_j$ : Q(9) = 396.51, p = 0.00											
Test of group differences: $Q_b(1) = 0.31$ ,	o = 0.5	8							_0		
						-6	-4	-2 0			
Random-effects REML model											

873 Random-effects REM

**874** Figure 9.

### Anti-obesity interventions in Mexican Population

			Medic	atior	n: Dias	stolic E	3P Cohen-d			
		Treatme	ent		Contr	ol		Cohen's d		Weight
Study	N	Mean	SD	N	Mean	SD		with 95% C	1	(%)
No T2D										
Morin 2001 (Form2)	51	74.34	9.16	26	76.78	10.65		-0.25 [ -0.73, 0	).22]	11.43
Morin 2001 (Form1)	59	71.39	8.16	26	76.78	10.65		-0.60 [ -1.07, -0	).13]	11.44
Gonzalez 2006 (Ezetimibe)	6	73	7	6	72	7		0.14 [ -0.99, 1	.28]	9.82
Meaney 2008 (Met+Diet)	22	75.52	11.36	17	80.35	7.82		-0.48 [ -1.13, 0	).16]	<u>11.11</u>
O'neil 2017 (Liraglutide)	339	75.5	8.7	189	116.5	13.9		-3.78 [ -4.07, -3	8.49]	11.69
Le Roux 2017 (Liraglutide)	783	77.1	9	327	77.9	9.3		-0.09 [ -0.22, 0	0.04]	11.82
Heterogeneity: $\tau^2 = 2.14$ , $I^2 = 98$	.47%,	$H^2 = 65$	5.18					-0.87 [ -2.06, 0	).33]	
Test of $\theta_i = \theta_j$ : Q(5) = 527.55, p =	= 0.00	)								
T2D										
Gonzalez 2004 (Met)	33	78	8	37	78	9		0.00 [ -0.47, 0	).47]	11.44
Gonzalez 2004 (Glim+Met )	34	82	6	37	78	9		0.52 [ 0.05, 0	.99]	11.44
Mendez 2017 (Met+Diacerein)	6	76.3	7.4	6	78.7	7.9		-0.31 [ -1.45, 0	.82]	9.81
Heterogeneity: $\tau^2 = 0.06$ , $I^2 = 40$	.12%,	$H^2 = 1.6$	67				•	0.18 [ -0.27, 0	0.63]	
Test of $\theta_i = \theta_j$ : Q(2) = 3.21, p = 0	0.20									
Overall							-	-0.56 [ -1.42, 0	0.30]	
Heterogeneity: $\tau^2 = 1.62$ , $I^2 = 97$	.64%,	$H^2 = 42$	.38							
Test of $\theta_i = \theta_j$ : Q(8) = 556.24, p =	= 0.00	)								
Test of group differences: Q <sub>b</sub> (1)	= 2.6	1, p = 0.	11							
							-4 -2 0	ר 2		
Random-effects REML model										
turidoni cheoto neme model										

#### Medication: Diastolic BP Cohen-d

876 Random-effects REML model

877 Figure 10.

Anti-obesity interventions in Mexican Population

- Table 1. Characteristics of the analyzed interventions (n=58). Duration of study: («) < 3 months,
- 880 (\*)  $\geq$  3 months to 9 months, (§)  $\geq$  12 months. **†** Frequency from 45 analyzed studies.

Category	Ν	%	References
Study Design			
A. Drugs	28	48.3	
A1. Non- diabetic patients	17 (* § «)	29.3	(24-38)
A2. Diabetic patients	11 (*)	19.0	(39-45)
B. Nutrition and exercise	28	48.3	
B1. Food and supplements	11 (* «)	19.0	(31, 46-54)
B2. Diet	6 (* «)	10.3	(50, 55-58)
B3. Behavioral	1 (*)	1.7	(59)
B4. Exercise	1 (*)	1.7	(60)
B5. Multi-component	7 (* «)	12.1	(50, 51, 60-62)
B6. Alternative	2 («)	3.4	(63-65)
C. Surgery	2	3.4	
C1. Cx	1 (§)	1.7	(67)
C2. Cx-diet	1 (*)	1.7	(68)
Gender †			
Male	5	11.1	(25, 28, 54, 60, 64)
Female	9	20	(29, 30, 50, 51, 57, 59, 61, 63, 68)
Both	31	68.9	(24, 26, 27, 31-49, 52-56, 58, 59, 62, 65, 67, 69)
Age †			
Youth (18-35)	11	24.4	(24, 46, 47, 49-51, 54, 58, 68)
Young adults (36-45)	21	46.7	(25, 27-29, 33-37, 39, 42, 43, 48, 52, 53, 56, 60-63, 69)
Older adults (46 or more)	13	28.9	(24, 26, 40-42, 44, 45, 57, 59, 65, 67)
City †			
México City	17	37.8	(29, 32, 35-38, 40, 41, 43, 45, 54, 59, 62, 63, 65, 67)
Guadalajara	13	28.9	(24, 25, 31, 33, 39, 42, 44, 47-49, 52, 56, 68)
Cd. Madero	3	6.7	(26, 27, 58)
Cuernavaca	2	4.4	(55, 69)
Durango	2	4.4	(57, 61)

### Anti-obesity interventions in Mexican Population

Querétaro	2	4.4	(50, 51)
Tijuana	2	4.4	(46, 64)
León	1	2.2	(60)
Monterrey	1	2.2	(34)
San Luis Potosí	1	2.2	(30)
Villahermosa	1	2.2	(53)

882

883

### 885 Table 2. Descriptive characteristics and assessment of Nutrition/behavior interventions.

Author State Year	Participants	Sample size	Intervention implemented/Control	Number of Participants (basal, final)	Treatment duration	Aims/Outcomes	Significance difference between groups
Moran <sup>62</sup> Mexico City 1997	Male and Female Intervention: 39 ± 15; Control: 38 ± 10 years old. BMI ≥30 Kg/m <sup>2</sup>	36	Intervention: diet + 750 mg ursodeoxycholic acid (AUD) + fiber placebo Control: diet + 15g Plantago psyllium (pp) + AUD placebo	Intervention: 18, 18 Control: 18, 18	2 months	<b>Primary:</b> prevention of gallstone disease (GD) in obese subjects undergoing a weight-reduction diet. Cholesterol crystals in duodenal bilis were used as surrogate of GD risk.	Yes: Treated individuals had less presence of cholesterol crystals.
Rodriguez- Hernandez <sup>61</sup> Durango 2009	Female 45.4 ± 10.4 years old BMI ≥30 Kg/m <sup>2</sup>	105	Intervention: Cognitive behavioral treatment + Low carb diet or low- fat diet Control: Non cognitive behavioral treatment	Intervention: 55, 52 Control: 50, 50	6 months	Primary: weight loss. Secondary: Depression and anxiety, fasting glucose and triglycerides.	Yes: CBT-LF had significant differences were observed in waist circumference, weight, and BMI in the and significantly decreased body fat, weight, BMI and triglycerides compared with C-LF group.
Ble-Castillo <sup>53</sup> Tabasco 2010	Male and Female 51.7 ± 5.6 years old BMI ≥30 Kg/m <sup>2</sup> T2DM	30	Intervention: Native Banana Starch Control: Soy Milk	Intervention: 15, 14 Control: 15, 14	2 months	Primary: Body weight and insulin sensibility. Secondary: Cholesterol; HDL; Triglycerides; Diastolic blood pressure; Systolic blood pressure; Waist to hip ratio; Calcium; Phosphates.	Yes: Body weight BMI, waist to hip ratic and triglycerides significantly reduced. No: No significant changes in glucose and HbA1c. A decrease in serum triglycerides in contro group. No changes were observed or calcium, phosphate and hematologica markers such as white blood cells, platelets and other indexes
Rodriguez- Hernandez <sup>57</sup> Durango 2011	Female Intervention: 46.3 $\pm$ 9.1; Control: 45 $\pm$ 9.1 years old. BMI $\ge$ 30 Kg/m <sup>2</sup>	59	Intervention: low carbs diet (LCD) Control: low fat diet (LFD)	Intervention: 31, 28 Control: 28, 26	6 months	<b>Primary:</b> To evaluate decrease aminotransferase levels.	No: No significan differences ir anthropometric and biochemical characteristics between groups

	NAFLD						
Rosado <sup>51</sup> Queretaro 2011	Female 34 ± 6 years old BMI ≥30 Kg/m <sup>2</sup>	139	Intervention 1: Low fat milk Intervention 2: Low fat milk with added micronutrients Control: No milk intake	Intervention 1: 46, 33 Intervention 2: 46, 37 Control: 47, 31	4 months	<b>Primary:</b> To evaluate anthropometrics, body composition, blood glucose levels, lipids profile, C-reactive protein, and blood pressure.	Yes: LFM+M group had significant weigh loss than control an LFM+M group. Boo fat among LFM+I group members wa significantly highe than LFM and control group.
							No: No difference between groups i glucose level, bloo lipid profile, bloo pressure, or C-reactiv protein level.
Madero <sup>58</sup>	Male and female	131	Intervention 1: Low	Intervention 1:	1.5 months	Primary: weight loss.	Yes: Significant weigl
Mexico City	Intervention 1:		fructose diet	65, 65		Secondary: Quality of life	loss compared wi baseline in bo
Mexico Oity	$37.56 \pm 1.14$ :		Intervention 2: Moderate	Intervention 2:		scores, blood pressure,	treatments, but high
2011	Intervention 2:		natural fructose diet	66, 66		lipid profile, serum	in the MNF grou
	40.15 ± 1.01.					glucose, insulin resistance,	Significant
	$BMI > 25 \text{ Kg/m}^2$					uric acid, and soluble intercellular adhesion	improvement
	BIVII > 25 Kg/III					molecule-1	secondary outcomes both treatments
Tovar <sup>50</sup>	Female	144	Intervention 1: Partial meal	Intervention 1:	3 months	Primary: weight reduction,	Yes: all group
Oueretere	Intervention 1		replacement (PMR) + Inulin	36, 23		blood lipids and	significantly reduce
Queretaro	Intervention 1: $34.62 \pm 7.4$ :		(INU)	Intervention 2:		micronutrients.	BMI, weight, waist ar hip circumferenc
2012	Intervention 2:		Intervention 2: PMR	36, 28			Subjects in PMR+IN
	33.17 ± 7.63;						PMR and IN
	Intervention 3:		Intervention 3: INU	Intervention 3:			significantly decrease
	32.58 ± 8.13; Control: 33.39 ±		Control: No additional	36, 30			triglycerides. Fiber intake increase
	8.72 years old.		treatment	Control: 36, 29			in PMR+INU and IN
				, -			groups. In PMR ar
	BMI ≥ 25 Kg/m <sup>2</sup>						PMR+INU group
							some minerals ar vitamins intake
							increased compare
							with INU and contr
							groups.
Martinez- Abundis <sup>49</sup>	Male and female	14	Intervention: Avocado Soybean Unsaponifiable	Intervention: 7, 7	3 months	Primary: Glucose, triglycerides, HDL□C,	No: No difference between groups befo
	Intervention: 35.4		(ASU)	Control: 7, 7		leptin, Coreactive protein	and after the tw
Jalisco	$\pm$ 4.3; Control:		(,)			(CRP), TNF $\alpha$ , adiponectin,	treatments in hs-CR
	35.4 ± 3.8 years		Control: Placebo			erythrocytes, fatty acids	IL-6, insulin secretio
2013	old.					and metabolic syndrome.	and insulin sensitivity

2015	old BMI 25-34.9 Kg/m <sup>2</sup> Hypertension according to WHO criteria		(Captopril/Telmisartan) <b>Control:</b> Anti-hypertensive therapy (captopril/Telmisartan)	Control: 70, 39			waist circumference and CRP showed differences at 3 and 6 months in the intervention group. HDL only when comparing baseline & 6 months. <b>No:</b> Leptin levels
Campos- Nonato <sup>55</sup> Morelos 2017	Male and female 47.4 ± 11.5 years old BMI 25-45 Kg/m <sup>2</sup> MetS	118	Intervention: High-Protein Diet Control: Standard-Protein Diet	Intervention: 59,59 Control: 59, 46	6 months	Primary: Evaluate the effect of increased protein intake on weight loss in adults with MetS. Secondary: (all measured in baseline, 3 and 6 months): fasting blood glucose, fasting insulin, hemoglobin A1c, total cholesterol, high-density lipoprotein (HDL) cholesterol, very-low- density lipoprotein (VLDL) cholesterol, triglycerides, C-reactive protein, creatinine, blood urea nitrogen, alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase.	Yes: Decreased weight, % of abdominal fat. Differences observed in both groups: waist circumference, Systolic blood pressure, fasting blood glucose, insulin, HOMA index, triglycerides, total cholesterol, VLDL cholesterol. The group SDP, presented a difference in HDL and direct bilirubin.
Leyva-Soto <sup>46</sup> Baja California 2018	Male and female Intervention: 23.8 ± 3.4; Control: 23.6 ± 3.5 years old. BMI > 29 Kg/m <sup>2</sup> MetS	92	Intervention: Dark chocolate Control: Milk Chocolate	Intervention: 42, 42 Control: 50, 42	6 months	Primary: Evaluate the genoprotective effect of consuming a flavonoids- rich chocolate. Secondary: Biochemical parameters related to cardiovascular risk and metabolic syndrome: changes in BMI, waist circumference, Fasting plasma glucose, HOMA, HbA1c, Systolic blood pressure, Diastolic blood pressure, Cholesterol total, triglyceride, Nuclear Abnormalities in Buccal	Yes: abnormalities of the nuclei in the buccal epithelial cells decreases significantly (less than 2%) after 6 months of daily consumption of 2g of dark chocolate. Decreased BMI, waist circumference, Total cholesterol, LDL Cholesterol, LDL Cholesterol, triglycerides, HOMA-IR, fasting plasma glucose, systolic and diastolic blood pressure in the group commercial dark

						Epithelial Cells.	chocolate.
Padilla- Camberos <sup>47</sup> Jalisco 2018	Male and female 20-55 years old BMI > 30 Kg/m <sup>2</sup>	28	Intervention: Agave fructans Control: Maltodextrin	Intervention: 14, 14 Control: 14, 14	3 months	Primary: Effects of agave fructans on weight control, lipid profile, and physical tolerability. Weight, hip, waist, hip waist index, total body fat (%), glucose, serum insulin, total cholesterol, (HDL) and (LDL) cholesterol, triglycerides.Secondary: serssments performed weight, hip, waist, hip waist index, total body fat (%), glucose, serum insulin, total cholesterol, triglycerides.	Yes: BMI and triglycerides of the Agave fructans treated group was reduced significantly from the baseline to the final measurements. Hip and waist circumference decreased in both groups. No: Glucose values

## 890

#### 891 892 Table 3. Descriptive characteristics and assessment of Medications.

armacological			assessment of Medicatio				
Author State Year	Participants	Sample size	Intervention implemented/Control	Number of Participants (basal, final)	Treatment duration	Aims/Outcomes	Significance difference between groups
Fanghänel <sup>41</sup>	Male and Female	60	Intervention: Metformin	Intervention: 30, 28	3 months	<b>Primary:</b> glucose and lipid metabolism.	Yes: Metformin had beneficia effects on insulin resistance
Mexico City	Intervention: 52.1 $\pm$ 8.8; Control: 51.2 $\pm$		Control: Insulin	<b>Control:</b> 30, 30		Secondary: Glycosylated	hypertension, overweight, an hyperlipidemia.
1996	8.5 years old.					hemoglobin, BMI, blood pressure.	
	BMI > 27 Kg/m <sup>2</sup>						
	NIDDM						
Fanghänel <sup>40</sup>	Male and Female	120	Intervention: Metformin, Insulin	Intervention: 60, 60	3 months	Primary: levels fibrinogen.	Yes: The insulin grout showed decrease on glucose
Mexico City	Intervention: $49.3 \pm 9.6$ ; Control: $47.1 \pm 100$		Control: Diet	<b>Control:</b> 60, 60			fibrinogen levels and BMI.
1998	7.3 years old.						
	BMI >27						
	T2DM						
Cuellar <sup>36</sup>	Male and female	69	Intervention: Sibutramine	Intervention: 35, 22	6 months	<b>Primary:</b> Safety and efficacy of sibutramine.	Yes: Sibutramine induce significant loss of body weigh and waist circumference. N
Mexico City	Intervention: 38.44 ± 10.09; Control:		Control: Placebo	<b>Control:</b> 34, 9		Secondary: waist	and waist circumference. N significant adverse events
2000	$38.62 \pm 9.12$ years old.					circumference and waist/hip	NOTE: Sibutramine wa
						ratio. Appetite, satiety, and diet adherence were also	withdrawn in 2010.
-onghängl <sup>37</sup>	BMI >30 Kg/m <sup>2</sup>	100	Intervention, Sikutromin	Intervention, FF, 40	C months	evaluated.	Vee Cikutromino indus
Fanghänel <sup>37</sup>	Male and female	109	Intervention: Sibutramine	Intervention: 55, 40	6 months	Primary: Safety and efficacy of sibutramine 10	Yes: Sibutramine induce significant loss of BMI an waist, but does no
Mexico City	Intervention: $38.09 \pm 10.11$ ; Control:		Control: Placebo	<b>Control:</b> 54, 44		mg.	waist, but does no significantly affe
2000	$39.48 \pm 10.26$ years old.					Secondary: Waist circumference and waist/hip	cardiovascular function. N significant adverse events
	BMI >30 Kg/m <sup>2</sup>					ratio, blood pressure and heart rate and clinical laboratory.	NOTE: Sibutramine wa withdrawn in 2010.
anghänel <sup>38</sup>	Male and female	82	Intervention: Sibutramine	Intervention: 40, 40	6 months	Primary: Endpoints for the	Yes: Patients had weigh
Mexico City	Intervention: 40.1 ± 10.51; Control:		Control: Placebo	<b>Control:</b> 44, 42		trial were the body weight and BMI.	gain, but they did not read the baseline body weight. N significant adverse events NOTE: Sibutramine wa withdrawn in 2010.
2001	$39.0 \pm 10.15$ years					Secondary: Endpoints	NOTE: Sibutramine wa

BMI >30 Kg/m <sup>2</sup>					ratio, appetite, satiety and diet adherence and adverse events.	
Male and Female Intervention 1: $36.84 \pm 9.16$ ; Intervention 2: $36.79 \pm 10.61$ ; Control: $36.77 \pm 9.18$ years old. BMI > 30 Kg/m <sup>2</sup>	210	Intervention 1: D- norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg, atropine 0.36 mg, aloin 16.2 mg. Intervention 2: D- norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg. Control: Placebo	Intervention 1: 69, 59 Intervention 2: 70, 51 Control: 69, 26	6 months	<b>Primary:</b> Update data on the efficacy and safety of two formulations of d- norpseudoephedrine in prolonged-release capsules, which have been used successfully in the treatment of obesity since 1956 and 1995.	Yes: The efficacy and safety of formulations 1 and 2 in the pharmacological treatment of obesity are confirmed, these d-norpseudoephedrine formulations maintain the weight reduction achieved for periods of at least six months, without causing addiction or inducing tolerance with loss of effectiveness after a shorted period. NOTE: Not approved by FDA.
Male and Female Intervention: 50.88 ± 1.37; Control: 50.79 ± 1.48 years old. BMI> 27 Kg/m <sup>2</sup> NIDDM	343	Intervention: Orlistat Control: Placebo	Intervention:169, 139 Control: 174, 141	6 months	Primary: To determine if obese non-insulin- dependent diabetic patients lose more weight when treated for 24 weeks with orlistat, in conjunction with a hypocaloric diet plus behavioral counselling, than when treated by placebo plus similar instructions. Secondary: To evaluate the effects on glucose profile and to determine the tolerability and safety of orlistat.	Yes: Orlistat group los greater body weight vs. in the placebo group, Orlistat treatment plus diet compared to placebo plus diet was associated with significant improvement in glycaemin control, as reflected in decreases in HbA1c, fasting plasma glucose and greater improvements that placebo in lipid profile, with reductions in total cholestered and LDL-c.
	Male and FemaleIntervention1: $36.84 \pm 9.16$ ;Intervention2: $36.79 \pm 10.61$ ;Control: $36.77 \pm$ $9.18$ years old.BMI > 30 Kg/m <sup>2</sup> Male and FemaleIntervention: $50.88 \pm$ $\pm$ $1.37$ ;Control: $50.79 \pm$ 1.48 years old.BMI > 27 Kg/m <sup>2</sup>	Male and Female       210         Intervention       1: $36.84 \pm 9.16$ ;         Intervention       2: $36.79 \pm 10.61$ ;         Control: $36.77 \pm 9.18$ 9.18 years old.         BMI > 30 Kg/m <sup>2</sup> Male and Female       343         Intervention: $50.88 \pm 1.37$ ; Control: $50.79 \pm 1.48$ years old.       BMI > 27 Kg/m <sup>2</sup>	Male and Female210Intervention 1: D- norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg, atropine 0.36 mg, aloin 16.2 mg.Intervention2: 36.79 $\pm$ 10.61; Control: 36.77 $\pm$ 9.18 years old.Intervention 2: D- norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg.BMI > 30 Kg/m²Intervention 2: D- norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg.Male and Female343Intervention: 50.88 $\pm$ 1.37; Control: 50.79 $\pm$ 1.48 years old.343Intervention: 50.79 $\pm$ 1.48 years old.Intervention: OrlistatBMI > 27 Kg/m²Intervention: Control: Placebo	Male and Female210Intervention 1: D- norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg, atropine 0.36 mg, aloin 16.2 mg.Intervention 1: 69, 59Intervention2: 36.79 $\pm$ 10.61; Control: 36.77 $\pm$ 9.18 years old.Intervention 2: D- norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg.Intervention 2: D- norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg.Control: 69, 26Male and Female343Intervention: Orlistat Control: PlaceboIntervention: 169, 139 Control: 174, 141Male and Female343Intervention: Orlistat Control: PlaceboIntervention: 169, 139 Control: 174, 141BMI> 27 Kg/m²Intervention: So SoSa SoIntervention: 174, 141	Male and Female210Intervention 1: D- norpseudoephedrine 50 mg, triidothyronine 75 ug, diazepam 5 mg, atropine 0.36 mg, aloin 16.2 mg.Intervention 1: 69, 596 monthsIntervention2: 36.79 $\pm$ 10.61; Control: 36.77 $\pm$ 9.18 years old.Intervention 2: D- norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg.Intervention 2: 70, 51Control: 69, 26IMI > 30 Kg/m <sup>2</sup> Intervention: Orlistat Control: PlaceboIntervention: 169, 1396 monthsMale and Female343Intervention: Orlistat Control: PlaceboIntervention: 169, 1396 monthsIntervention: 50.88 $\pm$ 1.37; Control: 50.79 $\pm$ 1.48 years old.343Intervention: Orlistat Control: PlaceboIntervention: 169, 1396 monthsBMI> 27 Kg/m <sup>2</sup> Image: State	BMI >30 Kg/m <sup>2</sup> diet adherence and adverse events.         Male and Female       210       Intervention 1: D- norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg, atropine 0.36 mg, aloin 16.2 mg.       Intervention 1: 69, 59       6 months       Firmary: Update data on the efficacy and safety of two formulations of d-norpseudoephedrine in prolonged-release capsules, which have been used successfully in the vention 2: 70, 51         S6.84 ± 9.16; Control: 36.77 ± 10.61; Control: 36.77 ± 0.18; Mitervention 2: D-norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg.       Intervention 2: D-norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg.       Control: 69, 26       Control: 69, 26         Male and Female       343       Intervention: Orlistat       Intervention: 169, 139       6 months       Primary: To determine if obese non-insulin-dependent idabetic patients iose non-insulin-solation 12: 70, 50.79 ± 1.48 years old.         BMI > 27 Kg/m <sup>2</sup> MIDDM       Intervention: Orlistat       Intervention: 169, 139       6 months       Primary: To determine if obese non-insulin-dependent diabetic patients iose havioral counselling, than when treated by placebo plus similar instructions.

medRxiv preprint doi: https://doi.org/10.1101/2021.05.27.21257740; this version posted May 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Gonzalez-Ortiz44	Male and Female	104	Intervention 1: Glimepiride	Intervention 1: 37, 37	3 months	<b>Primary:</b> To evaluate the efficacy and safety of	Yes: The percentage of patients that improved A1C
Jalisco 2004	Intervention 1: 53 $\pm$ 8; Intervention 2: 53 $\pm$ 7; Intervention		Intervention 2: Metformin Intervention 3: Glimepiride +	Intervention 2: 33,		glimepiride plus metformin in a single presentation, as combined therapy, in	patients that improved A1C levels to less than 7% were ir glimepiride, metformin and their combination groups.
2004	$33 \pm 7$ ; intervention 3: 53 ± 7 years old.		Metformin			patients with T2DM with	Their Compination groups.
	BMI >27 Kg/m <sup>2</sup>			<b>Intervention 3:</b> 34, 34		secondary failure to glibenclamide.	
	T2DM with A1c >					<u>y</u>	
	8%						-
Gómez-García <sup>54</sup>	Male	14	Intervention: Zinc sulfate	Intervention: 7, 7	30 days	Primary: Insulin sensitivity,	Yes: Zinc increased the leptor
		15			ou daye	leptin and androgens.	concentrations in obese.
Jalisco	Intervention: $21.8 \pm 2.8$ ; Control: $25.1 \pm 1.8$		Control: placebo	Control: 7, 7		Secondary: Glucose, total	No: No significant changes
2006	4.5 years old.					cholesterol, HDL-c, LDL-c,	insulin sensitivity ang
	BMI ≥27 Kg/m²					creatinine, uric acid, TT, TL, SHBG.	intervention.
Toplak <sup>34</sup>	Male and female	430	Intervention 1: Orlistat + Diet -500 kcal	<b>Intervention 1:</b> 215, 141	12 months	Primary: To determine the effect of two different levels	No: Treatment with orlistative was associated with
Multinational	Intervention 1: 41.3					of energy deficit on weight	clinically beneficial weigh
2005	$\pm$ 11.0; Intervention 2: 41.1 $\pm$ 12.1 years old.		Intervention 2: Orlistat + Diet -1000kcal	Intervention 2: 215, 154		loss in obese patients treated with orlistat.	No: Treatment with orlista was associated with clinically beneficial weigh loss, irrespective of the prescribed dietary energy restriction.
	BMI 30-43 Kg/m <sup>2</sup>						i i i i i i i i i i i i i i i i i i i
Gonzalez-Ortiz <sup>33</sup>	Male and Female	12	Intervention: Ezetimibe	Intervention: 6, 6	3 months	Primary: To evaluate the	Yes: Ezetimibe administered for 90 days decreased total
Jalisco	Intervention: 37.3 ±		Control: Placebo	<b>Control:</b> 6, 6		effect of ezetimibe on insulin sensitivity and lipid	and low-density lipoproter
2006	6.7; Control: $38.5 \pm 5.8$ years old.					profile in obese and dyslipidemic patients.	cholesterol concentrations.
	BMI: 25-35 Kg/m <sup>2</sup>						Yes: Metformin has effect of endothelial function and nitroxidation.
	Dyslipidaemia						
Meaney <sup>32</sup>	Male and female	60	Intervention: Metformin	Intervention: 30, 22	12 months	Primary: To evaluate the	Yes: Metformin has effect or
Mexico City	Intervention: 49 $\pm$ 10; Control: 49 $\pm$ 8		Control: Diet	Control: 28, 17		effect of metformin on metabolic syndrome in IGT patients.	nitroxidation. No: No-effect on BMI.
2008	years old.						
	MetS		luterusetiens Chitesee	la tempertien C. C.	0 endbe	Deimente basulia consitiuity	Mana Internet insuli
Hernandez- Gonzalez <sup>52</sup>	Male and Female	12	Intervention: Chitosan	Intervention: 6, 6	3 months	Primary: Insulin sensitivity.	Yes: Increased insuli sensitivity and decreased

Jalisco	Intervention: $41.6 \pm 6.3$ ; Control: $42.6 \pm 100$		Control: Placebo	<b>Control:</b> 6, 6		<b>Secondary:</b> Glucose, HDL- c, LDL-c and triglycerides.	weight, BMI, waist circumference and TG.
2010	5.6 years old.						weight, BMI, waist circumference and TG.
	BMI: 30-40 Kg/m <sup>2</sup>						
	Without DM						
Martinez- Abundis <sup>31</sup>	Male and female	18	Intervention 1: Placebo and metformin	Intervention 1: 9, 9	3 months	<b>Primary:</b> To compare the effect of metformin and	Yes: The three pharmacological interventions
	Intervention 1: 29.5			Intervention 2: 9, 9		sibutramine as	reduced RMI at different
Jalisco	$\pm$ 6.3; Intervention 2: 26.1 $\pm$ 4.0;		Intervention 2: Sibutramine and placebo	Intervention 3: 9, 9		monotherapy or as combined therapy on insulin	magnitudes. Metform improved insulin sensitivity Sibutramine decrease
2010	Intervention 3: 29.6 ± 5.5 years old.		Intervention 3: Sibutramine			sensitivity and adiposity in obese patients.	adiposity. Metformin as
			and metformin				monotherapy or combine
	BMI 30-40 Kg/m <sup>2</sup>					<b>Secondary:</b> To evaluated Blood pressure, ITT,	beneficial effect on liper
						glucose, total cholesterol, LDL-c, HDL-c, triglycerides.	profile.
Ramos-Zavala <sup>39</sup>	Male and female	40	Intervention: Diacerein	Intervention: 20, 20	2 months	Primary: Insulin secretion and metabolic control	Yes: Significant increases A first, late and total insuling
Jalisco	Intervention: 47.5 $\pm$ 5.3; Control: 47.7 $\pm$		Control: Placebo	<b>Control:</b> 20, 20		(included interleukin IL-Iß, TNF-a, IL-6).	fasting glucose and A16 levels, TNF-a, IL-6.
2011	5.2 years old.						
	BMI > 25						No: Without signification differences in total cholesterol, HDL-c, LDL-c
	T2DM with <6 months since diagnosis						triglycerides, VLDL-c and metabolized glucose
González-	Women	60	Intervention 1: 1 g of	Intervention 1: 20,	3 months	Primary: To assess the	Yes: Supplementation
Acevedo <sup>30</sup>	Intervention 1:		Omega-3	20		effect of omega-3 supplementation on BMI,	BMI, and total fat mass
San Luis Potosi	31.65 ± 7.41; Intervention 2:		Intervention 2: 2 g of Omega-3	Intervention 2: 20, 20		WHI and body composition of obese women using	compared to the contrating group, a dose-response
2013	28.45 ± 8.15;		Control: Placebo+ Vitamin E	-		bioelectrical impedance.	effect, but these effects depended on the time and
	Control: $30.70 \pm 6.87$ years old		(200 IU)	<b>Control:</b> 20, 20			annound on Onnega 3
	BMI > 30 Kg/m <sup>2</sup>						supplemented, when the degree of compliance of
	5						exercise, adherence to the diet and age were controlled.

posted May 30, , 2021 The copyright holder for this preprint to display the preprint in perpetuity.

anchez-Muñoz <sup>29</sup>	Women	19	Intervention: Metformin	Intervention: 9, 8	3 months	<b>Primary</b> : To establish the effectiveness of aerobic	Yes: It was significative changes in Arterial tension
Mexico City 2013	25-60 years old BMI >24,9 Kg/m <sup>2</sup>		Control: Exercise	Control: 10, 8		exercise and its influence in reducing cardiovascular risk in overweight or obese women with NAFLD.	HOMA-IR and insulin. <b>No:</b> Was not significative differences in fatty liver.
Hernandez- Corona <sup>48</sup> Jalisco 2014	Male and female Intervention: $45.4 \pm$ 7.3; Control: $42.4 \pm$ 3.7 years old. BMI: 25-34.9 Kg/m <sup>2</sup>	25	Intervention: F Fucoidan Control: Placebo	Intervention: 13, 11 Control: 12, 8	3 months	Primary: Evaluate changes in insulin secretion and insulin resistance. Secondary: Weight, blood pressure, glucose, total cholesterol, HDL-c, TG and IR.	Yes: Significant decrease in DBP and LDL-c, Increase in insulin levels, HOMA B-cells and HOMA IR. No: BMI.
Hernandez- Bastida <sup>43</sup> Mexico City 2015	Male and female 18-65 years old BMI 25-40 Kg/m <sup>2</sup> T2DM	120	Intervention: Topiromate + Phentarmine Control: Placebo + Phentarmine	Intervention: 60, 54 Control: 60, 53	3 months	Primary:Efficacy and safety of the combination of phentermineplus topiramate.plus topiramate.Secondary:To evaluate the combination over risk and safety factors.	Yes: The combination showed reduction in weigh BMI, waist, circumference lipids and glucose. The most frequent adverse events were paresthesia and dry mouth these effects decreased in frequency and intensity during the study.
O´Neil <sup>27</sup> Multinational 2016	Male and female <b>Hispanic Age:</b> Intervention: 41.4 ± 11.4; Control: 41.0 ± 11.7 years old. BMI ≥27 Kg/m <sup>2</sup> with at least 1 comorbid condition or BMI ≥30 Kg/m <sup>2</sup>	5131 Hispanic: 534	Intervention: Liraglutide Control: Placebo	Intervention: 3289, 3289 Control: 1842, 1842 Hispanic participants: Intervention: 341, 341 Control: 193, 193 (their data were combined with other ethnic groups)	3 studies of 56 weeks 1 study of 32 weeks	<b>Primary:</b> Efficacy and safety of liraglutide. <b>Secondary:</b> Weight and risk factors.	Yes: Efficacy and safety were largely similar between Hispanic and non-Hispanic.

Sánchez- Rodriguez <sup>28</sup> Mexico City	Healthy postmenopausal women or with MetS.	100	Intervention: Hormone therapy Control: Placebo	Intervention: 50, 46 Control: 50, 45	6 months	Primary: Oxidative stress.	Yes: After 6 months, MetS decreased in the hormone treated group (48%), triglycerides and HDL-c; the controls did not show
2016	Healthy women: Intervention: $52 \pm 0.6$ ; Control: $53 \pm 0.7$ years old. MetS women: Intervention: $52 \pm 0.7$ ; Control: $53 \pm 0.9$ years old.						differences. SS in MSW-HT decreased ( $3.8 \pm 0.3$ to $1.7 \pm 0.3$ , p < 0.05) and Oxidative stress was also reduced (44%), this effect was evident since 3 mo. HW-HT with high OS also decreased (40%).
N	,	10	had a managed base. Manufacture in a	Internetien 0.0	0	<b>D</b> elements Observations start	no change.
Mendez-del Villar <sup>42</sup> Jalisco 2017	Male and Female Intervention: $41.3 \pm$ 9.7; Control: $54 \pm$ 3.5 years old. BMI: 25-34.9 Kg/m <sup>2</sup> T2DM and inadequate glycemic control	12	Intervention: Metformin + Diacerein Control: Metformin	Intervention: 6, 6 Control: 6, 6	3 months	Primary: Glycemic control.	Yes: Significant decrease in a fasting glucose, postprandial a glucose and A1C.
Gonzalez-	Male and female	16	Intervention: Linagliptin	Intervention: 8, 8	3 months	Primary: To assess the	Yes: Group with linaglipting had decrease in glucose
Heredia <sup>24</sup> Jalisco 2017	Intervention: $49.3 \pm$ 5.7; Control: $51.9 \pm$ 6.4 years old. BMI 25–34.9 Kg/m <sup>2</sup> Impaired Glucose		Control: Metformin	Control: 8, 8		effect of linagliptin versus metformin on glycemic variability in patients with IGT.	had decrease in glucose levels at 120 min of OGTT. No: No significant difference in the AUC, MAGE, SD glucose, CV of glucose, and MBG between groups.
onzalez-Ortiz <sup>25</sup>	Tolerance Male	18	Intervention: Taladafil	Intervention: 9, 9	28 days	Primary: Blood pressure,	No: After the administration of
Jalisco 2017	Intervention: $40.2 \pm$ 7.9; Control: $38.4 \pm$ 6.4 years old.		Control: Placebo	<b>Control:</b> 9, 9		cholesterol, triglycerides, HDL-c, LDL-c, glucose.	tadalafil there were no significant differences in tota insulin secretion first phase o
	BMI 30-39.9 Kg/m <sup>2</sup>						sensitivity. No significan differences were shown ir other measurements. Yes: Time to onset o
Le Roux <sup>26</sup>	Male and female	2254	Intervention: Liraglutide	Intervention: 1505, 783	40 months (3.3 years)	<b>Primary</b> : Evaluate the proportion of individuals	Yes: Time to onset o diabetes over the 40 months
Multinational	Intervention: $47.5 \pm$	Hispanic:	Control: Placebo	<b>Control:</b> 749, 327	yearsy	with prediabetes who were	among all randomized
2017	11.7; Control: 47.3 ± 11.8 years old.	213		<b>Control:</b> 749, 327		diagnosed with type 2 diabetes.	individuals was 2.7 times longer with liraglutide that

	BMI ≥27 Kg/m <sup>2</sup>		Hispanic participants	Secondary: GLP-1	with placebo.
	Bivii ≥27 Rg/III		Intervention: 143	receptor agonist, waist	
	Dyslipidemia, or		intervention. 145	circumference (cm),	
	hypertension, or		Control: 70	glycated hemoglobin (%), 2-	placebo at month 40: BMI, a waist circumference, glycated
	both			h plasma glucose during	hemoglobin, fasting glucose,
	bour		(their data were	OGTT (mmol/L), Free fatty	fasting insulin, fasting C-
			gathered with other	acids (mmol/L), Blood	peptide, glucose levels in
			individuals)	pressure (mm Hg).	OGTT, systolic and diastolic
				1 (	blood pressure, and heart
					rate.
NIDE	DM: Non-insulin dependent diabetes r	nellitus; BMI: Boo	y mass index; T2DM: Type 2 diabetes mellitus; FDA: Foo	od and Drug Administration; A1c: Glycated hemoc	globin; HDL: High
dens	sity lipoprotein: LDL: Low density lipo	proteins: VLDL:	Very low density lipoprotein; TT: Total testosterone, TL:	: Free testosterone. SHBG: Sex Hormone Binding	Globulin: MetS:
		•	Triglycerides; ITT: Insulin tolerance test; IL-Iß: Interleuki		S S S S S S S S S S S S S S S S S S S
	, , , , ,		isease; IR: Insulin resistance; HOMA-IR: Homeostasi		
vvi ii.	. Waist hip much, NAI LD. Non-ait	onone ratty river of		is model assessment of it, noma becens. no	
1000	compart hate call function: CC: Street	ACCORD MENA	Mote women were assigned to UT (hormone thereas)	); UW UT; Haalthy harmona tharany; OS; Ovidativ	
	,	,	: MetS women were assigned to HT (hormone therapy)	,, , , , , , , , , , , , , , , , , , ,	ve stress; OGTT: ۵ تَ
Oral	glucose tolerance test; AUC: Area	,	: MetS women were assigned to HT (hormone therapy) MAGE: Mean amplitude of glycemic excursion, SD: St	,, , , , , , , , , , , , , , , , , , ,	ve stress; OGTT: av is BG: Mean blood aite
Oral	,	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	ve stress; OGTT: e vaite BG: Mean blood aire be au
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	ve stress; OGTT: e available BG: Mean blood aliable utho
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	ve stress; OGTT: e available BG: Mean blood allable uthor/f
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	BG: Mean blood author/fun e under un
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	BG: Mean blood althor/fun er under u
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	BG: Mean blood althor/fun e under un
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	BG: Mean blood althor/fun under under unde
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	BG: Mean blood althor/fun er under u
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	BG: Mean blood author/fun er under u
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	BG: Mean blood althor/fun er under u
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	BG: Mean blood author/fun er under u
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )	,, , , , , , , , , , , , , , , , , , ,	ve stress; OGTT: BG: Mean blood BG: Mean blood e available under a CC-BY-NC-ND 4.0 Inter
Oral	glucose tolerance test; AUC: Area	,	<b>5</b> ( 1 <i>3</i> )		BG: Mean blood aid blood aid blood aid blood blod bl

#### 902 Table 4. Descriptive characteristics and assessment of Medications.

903

Author State Year	native Intervention Participants	Sample size	Intervention implemented/Control	Number of Participants (basal, final)	Treatment duration	Aims/Outcomes	Significance difference between groups
Robles- Cervantes <sup>68</sup> Jalisco 2007	Female Intervention: 34.0 $\pm$ 3.7; Control: 34.6 $\pm$ 3.6 years old. BMI: 30-33 Kg/m <sup>2</sup>	12	Intervention: Liposuction and diet Control: Diet	Intervention: 6, 6 Control: 6, 6	6 months	Primary: Visceral fat, Insulin sensitivity, leptin and tumor necrosis factor alfa.         Secondary: Glucose, Creatinine, Uric acid, Total cholesterol, HDL cholesterol, Triglycerides.	Yes: Leptin correlated with the subcutaneous fat. No: no significant difference in insulin sensitivity and did not correlate with subcutaneous fat, leptin, or TNF-alpha.
Arceo-Olaiz <sup>67</sup> Mexico City 2008	Male and Female Intervention: 36.5 ± 9.7; Control: 37.8 ± 9.6 years old. BMI: 40-55 kg/m2	60	Intervention: Laparoscopic roux- en - y gastric bypass (LRYGB) Control: banded LRYGB (BLRYGB)	Intervention: 30, 30 Control: 30, 30	24 months	Primary: Weight loss	<b>No:</b> The studied groups di not have significar differences in weight loss a 6, 12, and 24 months. Th frequency of complication was similar in both groups.
García-Vivas <sup>63</sup> Durango 2014	Women 18-45 years old BMI ≥25 Kg/m <sup>2</sup> without known MetS	138	Intervention: Accupunture Control: Sham Accupunture	138, 99	2 months	<b>Primary:</b> anthropometric and biochemical	Yes: Acupoint catgue embedding therapy moxibustion produce significant reduction in bod weight insulin and HOMA-IR
Alvarado- Reynoso <sup>65</sup> Mexico City 2019	Male and Female Intervention: 42.1 ± 3.2; Control: 37.8 ± 3.3 years old. BMI≥ 25 Kg/m <sup>2</sup>	45	Intervention: repetitive transcranial magnetic stimulation) rTMS Control: sham rTMs	Intervention: 22, 18 Control: 23, 19	2 weeks	<b>Primary:</b> body weight, food craving, auto perception, general health, depression and anxiety	Yes: In the rTMS-treate group reduced body weigh anxiety, and food craving General health surve domain improved on physica functioning, emotional role and vitality. The body shap questionnaire improved.
rnandez-Lepe <sup>64</sup> Chihuahua 2019	Male 25 ± 5 years old BMI >25 Kg/m <sup>2</sup> Sedentary	52	Intervention: spirulina maxima Control: placebo	Intervention: 26, 26 Control: 26, 26	3 months	<b>Primary:</b> plasma lipid profile and antioxidant capacity	Yes: BMI, total cholestero triglycerides and LDL- decreased. HDL-C increase in all treatment groups Participants with know dyslipidemia had highe response.

#### 905 Table 5. Network meta-analysis results matrix.

Matrix A: Drugs (Non-diabetic participants)								
BMI (Reference: placebo)								
DHA 470 + EPA	0.072 (-0.672,	0.143 (-0.852,	0.129 (-0.872,	-0.365 (-1.192,	-0.816 (-1.582, -0.049)			
580	0.815)	1.138)	1.130)	0.462)				
-0.072 (-0.815,	DHA 940 + EPA	0.071 (-0.927,	0.057 (-0.947,	-0.436 (-1.267,	-0.888 (-1.658, -0.117)			
0.672)	1160	1.070)	1.061)	0.394)				
-0.143 (-1.138,	-0.071 (-1.070,	Form1	-0.014 (-0.570,	-0.508 (-1.214,	-0.959 (-1.593, -0.324)			
0.852)	0.927)		0.541)	0.198)				
-0.129 (-1.130,	-0.057 (-1.061,	0.014 (-0.541,	Form2	-0.493 (-1.208,	-0.944 (-1.588, -0.301)			
0.872)	0.947)	0.570)		0.221)				
0.365 (-0.462,	0.436 (-0.394,	0.508 (-0.198,	0.493 (-0.221,	Liraglutide	-0.451 (-0.761, -0.141)			
1.192)	1.267)	1.214)	1.208)					
0.816 ( 0.049,	0.888 ( 0.117,	0.959 ( 0.324,	0.944 ( 0.301,	0.451 ( 0.141,	Plc			
1.582)	1.658)	1.593)	1.588)	0.761)				

#### Matrix B: Drugs (Diabetic participants)

#### **BMI (Reference: metformin)**

Diac+Met	-0.080 (-1.307, 1.147)	-0.143 (-1.374, 1.088)	-0.774 (-2.026, 0.478)	0.124 (-1.009, 1.257)				
0.080 (-1.147, 1.307)	Glim	-0.063 (-0.529, 0.403)	-0.694 (-1.404, 0.017)	0.204 (-0.266, 0.675)				
0.143 (-1.088, 1.374)	0.063 (-0.403, 0.529)	Glim+Met	-0.631 (-1.349, 0.087)	0.267 (-0.214, 0.749)				
0.774 (-0.478, 2.026)	0.694 (-0.017, 1.404)	0.631 (-0.087, 1.349)	Insulin	0.898 (0.366, 1.431)				
-0.124 (-1.257, 1.009)	-0.204 (-0.675, 0.266)	-0.267 (-0.749, 0.214)	-0.898 (-1.431, -0.366)	Met				

906

Matrix A represent the estimates of the effect of treatments (standardized mean differences and 95%Cl) relative to placebo. The dosage of DHA and EPA are in mg per day. Form1: D-norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg, atropine 0.36 mg, aloin 16.2 mg. Form2: D-norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg. These two formulations are not approved by FDA. Plc: Placebo. Matrix B shows estimates of the effect of treatments (standardized mean differences) relative to metformin in patients with diabetes. Diac: Diacerin; Gim: Glimepiride; Met: Metformin.